



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/12, C07K 14/705, G01N 33/68	A2	(11) International Publication Number: WO 00/70044 (43) International Publication Date: 23 November 2000 (23.11.2000)
(21) International Application Number: PCT/US00/12383 (22) International Filing Date: 08 May 2000 (08.05.2000) (30) Priority Data: 60/134,063 13 May 1999 (13.05.1999) US 60/137,547 04 June 1999 (04.06.1999) US (60) Parent Application or Grant THE JOHNS HOPKINS UNIVERSITY [/]; (). MITTMAN, Scott [/]; (). AGNEW, William, S. [/]; (). MITTMAN, Scott [/]; (). AGNEW, William, S. [/]; (). KAGAN, Sarah, A. ; ().	Published	

(54) Title: HUMAN BRAIN T CALCIUM CHANNEL ALPHA-SUBUNIT SPLICE VARIANTS
(54) Titre: VARIANTS EPISSÉS DE LA SOUS-UNITÉ ALPHA DES CANAUX CALCIUM T DANS LE CERVEAU HUMAIN

(57) Abstract

The structures of CACNA1G and CACNA1I, the genes encoding the human brain T Ca^{2+} channel 'alpha' ζ 1G and 'alpha' ζ 1I subunits, respectively, were determined by comparison of polymerase chain reaction-amplified brain cDNA and genomic sequences. CACNA1G consists of at least 38 exons spanning at least 66,490 basepairs of chromosome 17q22. Alternative splicing of the RNA occurs at six sites: cassette exons 14, 26, 34 and 35, an internal donor in exon 25 and protein-coding intron 38B. Additionally, the RNA can be polyadenylated at either of two sites. Alternative splicing of CACNA1G RNA may lead to expression of as many as 64 distinct protein products, ranging from 2,171 to 2,377 amino-acids residues, with as many as 45 potential phosphorylation sites. CACNA1I consists of at least 37 exons spanning at least 116,390 basepairs of chromosome 22q12.3-13.2. Alternative splicing of the gene occurs at three sites: cassette exon 9, an alternative acceptor in exon 33 and mutually-exclusive 3' exons 36B and 37. Alternative splicing of CACNA1I RNA may lead to expression of as many as 8 distinct protein products, ranging from 1,968 to 2,223 amino-acids residues, with as many as 28 potential phosphorylation sites. Molecular diversity generated by alternative splicing and post-translation modification of these and other members of the T 'alpha' ζ 1 subunit gene family may account for the observed heterogeneity of T currents in central neurons.

(57) Abrégé

Dans cette invention on a déterminé les structures de CACNA1G et de CACNA1I, gènes codant les sous-unités 'alpha' ζ 1G et 'alpha' ζ 1I, respectivement, du canal T Ca^{2+} dans le cerveau humain, en comparant des ADNc du cerveau amplifiés par PCR et des séquences génomiques. CACNA1G est constitué d'au moins 38 exons recouvrant au moins 66 490 paires de base du chromosome 17q22. L'épissage alternatif de l'ARN a lieu dans six sites: exons de cassette 14, 26, 34 et 35, donneur interne dans l'exon 25 et intron 38B codant des protéines. En outre, l'ARN peut être polyadénylé dans n'importe lequel de ces deux sites. L'épissage alternatif d'ARN CACNA1G peut mener à l'expression de jusqu'à 64 produits protéiques distincts, compris entre les résidus d'acides aminés 2171 et 2377, avec jusqu'à 45 sites potentiels de phosphorylation. CACNA1I consiste d'au moins 37 exons recouvrant au moins 116 390 paires de base du chromosome 22q12.3-13.2. L'épissage alternatif de l'ARN a lieu dans trois sites: exon de cassette 9, accepteur alternatif dans l'exon 33 et introns 36B et 37 de 3' s'excluant mutuellement. L'épissage alternatif d'ARN CACNA1I peut mener à l'expression de jusqu'à 8 produits protéiques distincts, compris entre les résidus d'acides aminés 1968 et 2223, avec jusqu'à 28 sites potentiels de phosphorylation. La diversité moléculaire, générée par l'épissage alternatif et la modification post-traductionnelle de ces membres et d'autres membres de la famille de gènes de sous-unité 'alpha' ζ 1G de T, peut refléter l'hétérogénéité observée des courants T dans les neurones centraux.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, G01N 33/68		A2	(11) International Publication Number: WO 00/70044
			(43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/US00/12383		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 May 2000 (08.05.00)		Published Without international search report and to be republished upon receipt of that report.	
(30) Priority Data: 60/134,063 13 May 1999 (13.05.99) US 60/137,547 4 June 1999 (04.06.99) US			
(71) Applicant (for all designated States except US): THE JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market Place, Baltimore, MD 21201 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): MITTMAN, Scott [US/US]; The Johns Hopkins University, 111 Market Place, Baltimore, MD 21201 (US). AGNEW, William, S. [US/US]; The Johns Hopkins University, 111 Market Place, Baltimore, MD 21201 (US).			
(74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff, Ltd., Eleventh Floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).			
(54) Title: HUMAN BRAIN T CALCIUM CHANNEL ALPHA-SUBUNIT SPLICE VARIANTS			
(57) Abstract			
<p>The structures of <i>CACNA1G</i> and <i>CACNA1I</i>, the genes encoding the human brain T Ca^{2+} channel α_{1G} and α_{1I} subunits, respectively, were determined by comparison of polymerase chain reaction-amplified brain cDNA and genomic sequences. <i>CACNA1G</i> consists of at least 38 exons spanning at least 66,490 basepairs of chromosome 17q22. Alternative splicing of the RNA occurs at six sites: cassette exons 14, 26, 34 and 35, an internal donor in exon 25 and protein-coding intron 38B. Additionally, the RNA can be polyadenylated at either of two sites. Alternative splicing of <i>CACNA1G</i> RNA may lead to expression of as many as 64 distinct protein products, ranging from 2,171 to 2,377 amino-acids residues, with as many as 45 potential phosphorylation sites. <i>CACNA1I</i> consists of at least 37 exons spanning at least 116,390 basepairs of chromosome 22q12.3-13.2. Alternative splicing of the gene occurs at three sites: cassette exon 9, an alternative acceptor in exon 33 and mutually-exclusive 3' exons 36B and 37. Alternative splicing of <i>CACNA1I</i> RNA may lead to expression of as many as 8 distinct protein products, ranging from 1,968 to 2,223 amino-acids residues, with as many as 28 potential phosphorylation sites. Molecular diversity generated by alternative splicing and post-translation modification of these and other members of the T α_1 subunit gene family may account for the observed heterogeneity of T currents in central neurons.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

5

10

15

20

25

30

35

40

45

50

55

HUMAN BRAIN T CALCIUM CHANNEL
ALPHA-SUBUNIT SPLICE VARIANTS

This invention was made using funds from the U.S. government. Under the terms of NIH grants K08NS01939 and P50HL52307, the government may retain certain rights in the invention.

TECHNICAL FIELD OF THE INVENTION

This invention is related to ion channels. In particular, it is related to ion channels related to brain function.

BACKGROUND OF THE INVENTION

Voltage-dependent calcium channels are involved in both coupling electrical activity to calcium influx and contributing to membrane properties. Low voltage-activated (LVA) calcium channels activate at potentials near the resting membrane potential. LVA participate in spike-induced calcium entry and allow calcium influx at potentials below threshold. LVA calcium channels also are involved in subthreshold membrane fluctuations. LVA calcium channel dysfunction is implicated in epileptiform activity. Moreover, these channels are targets for antiepileptic drugs.

T-type (transient) properties in neurons include low voltage activation, strongly voltage-dependent kinetics, rapid inactivation, slow deactivation, and small single-channel conductance.

Recently, a subfamily of genes (designated Ca_vT) has been discovered encoding α_1 subunits that are ~ 30% homologous to HVA subunit genes in their putative membrane-spanning regions.

T currents are a diverse class of Ca^{2+} current characterized by a low voltage threshold for activation. Proposed functions include generation of low-threshold spikes that lead to bursting, promotion of voltage oscillations, boosting of Ca^{2+} entry and synaptic potentiation. T currents may be the targets of succinimides and related compounds administered in the treatment of absence epilepsy. Recently, cDNA sequences of three T α_1 subunits, rat α_{1G} and α_{1I} and human α_{1H} , have been reported.

Ca^{2+} channel α_1 subunits are encoded by at least 10 genes falling into three subfamilies: ABE, SCDF and GHI¹. Alternative splicing of α_1 RNAs generates further molecular diversity. There is a need in the art for identifying the different splice forms of the calcium channel subunits, so that they can be used as targets in drug discovery and development programs.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide an isolated and purified α_{1G} subunit of human brain T calcium channel.

It is an object of the present invention to provide an isolated and purified nucleic acid encoding the α_{1G} subunit.

It is an object of the present invention to provide an isolated and purified α_{1I} subunit of human brain T calcium channel.

It is an object of the present invention to provide an isolated and purified nucleic acid encoding the α_{1I} subunit.

It is another object of the present invention to provide an isolated and purified nucleic acid comprising an exon of a human brain T calcium channel alpha subunit.

Another object of the invention is to provide an isolated and purified polypeptide which comprises a translated exon of a human brain T calcium channel.

¹ The gene encoding the subunit α_{1X} , where X is A - I, or S, is denoted *CACNA1X*. Alternative names for the SCDF and GHI subfamilies are L and T, respectively.

5 Another object of the invention is to provide expression vectors and host cells for expressing the subunits of human brain T calcium channel.

10 Another object of the invention is to provide a method to identify candidate drugs for treating epilepsy.

15 These and other objects of the invention are achieved by one or more of the embodiments described below. In one embodiment an isolated and purified α_{1G} subunit of human brain T calcium channel is provided. The subunit is selected from splice variants 1-64 as shown in Table 1.

20 According to another object of the invention an isolated and purified nucleic acid encoding the α_{1G} subunit is provided.

25 According to still another object of the invention an isolated and purified polypeptide is provided which comprises a translated exon selected from the group consisting of 1-38D as shown in Table 2.

30 Another embodiment of the invention is an isolated and purified nucleic acid which comprises an exon selected from the group consisting of 1-38D as shown in Table 2.

35 Still another embodiment of the invention is an isolated and purified α_{1I} subunit of human brain T calcium channel selected from splice variants 1-8 as shown in Table 3.

40 The present invention also provides an isolated and purified polypeptide which comprises a translated exon selected from the group consisting of 1-37 as shown in Table 4.

45 According to another aspect of the invention an isolated and purified nucleic acid is provided which comprises an exon selected from the group consisting of 1-37 as shown in Table 4.

50 Vectors and host cells which contain and/or express any of the nucleic acids, polypeptides or proteins described above are also contemplated as part of the present invention.

55 Other embodiments of the invention are methods to identify candidate drugs for treating epilepsy. A host cell containing a nucleic acid encoding an α_{1G} or α_{1I} subunit or exon is contacted with a test substance. Uptake by the cell of calcium ions is measured. A test substance which inhibits the uptake by the cell of calcium ions is identified as a candidate drug for treating epilepsy.

These and other embodiments of the invention which will be described in more detail below, and which will be evident to those of ordinary skill in the art upon reading the disclosure, provide the art with new drug discovery targets which can form the basis of a drug screening program.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1. Map of *CACNA1I* and α_{1I} cDNA. In the genomic map (bottom), exons are indicated by vertical bars and introns by the connecting horizontal line. The smallest exons are not to scale due to the minimum line thickness required for printing. In the cDNA map (middle), constitutively-spliced, odd-numbered exons are black and even-numbered exons, gray. Alternatively-processed exons (or portions of exons) are colored as follows: 9 – red, 33A – orange, 36B – green. The thinner portions of exons 1 and 36 represent the 5' and 3' untranslated regions, respectively. Selected exons are labeled to facilitate counting. Black bars above this cDNA map indicate relative PCR product locations. Four of the bars are interrupted by a thin line to indicate portions deleted by alternative splicing. Exon 37 (blue) is mutually exclusive with exon 36, requiring a separate representation of the 3' end of the cDNA, at the top. Only a small portion of the exon 37 3' UTR has been amplified and sequenced. Two of the PCR products containing portions of exon 37 are represented as black bars above the partial cDNA map. The starred scale bar equals 1 kb for PCR products and the cDNA maps and 15 kb for the genomic map.

Fig. 2. Schematic of the predicted α_{1I} protein. Each aa residue is represented by a small circle. In the large cytoplasmic and extracellular loops, a full up-down cycle measures 100 residues. Main features of the topology are labeled in large type and described in the text. Portions of the protein derived from odd-numbered exons are labeled in small type. A similarity score was computed for each residue from alignments of the aa sequence of each α_{1I} exon with the sequences of the homologous human α_{1G} and α_{1H} exons by iterative pairwise use of gap with default parameters. *Pipe*, *colon*, *period* and *space* similarity symbols were assigned numerical values of 3, 2, 1 and 0, respectively; α_{1I} vs. α_{1G} and α_{1I} vs. α_{1H} scores for an individual α_{1I} residue were added to yield a final score of 0 to 6. Residue identity in all three proteins produced a score of 6; pairing of an α_{1I} residue with unrelated amino acids in both alignments produced

a score of 0. Exons 9, 34 and 35 had no apparent α_{1G} or α_{1H} homologues; these residues are uncolored. Exon 16 had only an α_{1H} homologue and exons 33 and 37 had only α_{1G} homologues; the maximum possible similarity score for these exons is 3. Portions of the protein deleted by alternative splicing have a light blue background. Mutually exclusive exons 36B (7 aa) and 37 (214 aa) are side-by-side. Extracellular cysteines, potential N-glycosylation and phosphorylation sites and the location of splice sites (mapped to the protein product) are indicated by the appropriate symbols. Symbol colors have the following meanings: black – conserved among all human α_1 subunits; purple – conserved within 3 aa residues in the multiple sequence alignment of all human α_1 subunits; blue – conserved among the human ABE and GHI subfamilies; green – conserved among all human T α_1 subunits; brown – also present in human α_{1H} ; orange – also present in human α_{1G} ; pink – unique to α_{1H} . PKA: cyclic-nucleotide-dependent protein kinase phosphorylation site, PKC: protein kinase C phosphorylation site, CKII: casein kinase II phosphorylation site, Tyr: tyrosine kinase phosphorylation site. One residue in the C-terminus was identified as a potential site for phosphorylation by both PKA and CKII; another was identified as a potential site for phosphorylation by both PKA and PKC.

Fig. 3. Map of *CACNA1G* and the α_{1G} cDNA. In the genomic map (bottom), exons are indicated by vertical bars and introns by the connecting horizontal line. The smallest exons are not to scale due to the minimum line thickness required for printing. In the cDNA map (middle), constitutively-spliced, odd-numbered exons are gray and even-numbered exons, black. Alternatively-processed exons (or portions of exons) are colored as follows: 14 – olive, 25B – red, 26 – blue, 34 – light green, 35 – orange, 38B – dark green, 38D – purple. The thinner portions of exons 1 and 38 represent the 5' and 3' untranslated regions, respectively. Selected exons are labeled to facilitate counting. Black bars at the top of the figure indicate PCR product locations relative to the cDNA map. Nine of the bars are interrupted by a thin line to indicate portions deleted by alternative splicing. Red bars (labeled with GenBank accession numbers) represent infant brain cDNA clone ESTs. For one clone, only a 3' EST has been reported. Thin lines indicate portions deleted by alternative splicing

and dashed lines indicate unsequenced portions. The starred scale bar equals 1 kb for PCR products and the cDNA map and 10 kb for the genomic map.

Fig. 4. Schematic of predicted α_{IG} proteins. Each aa residues is represented by a small circle. In the large cytoplasmic and extracellular loops, a full up-down cycle measures 100 residues. Main features of the topology are labeled in large type and described in the text. Portions of the protein involved in alternative splicing have a blue background. These and portions derived from odd-numbered exons are labeled in small type. A similarity score was computed for each residue from alignments of the aa sequence of each α_{IG} exon with the sequences of the homologous human α_{IH} (unpublished observations) and α_{II} (submitted) exons by iterative pairwise use of *gap* (Genetics Computer Group, Wisconsin Package Version 9.0) with default parameters. *Pipe*, *colon*, *period* and *space* similarity symbols were assigned numerical values of 3, 2, 1 and 0, respectively; α_{IG} vs. α_{IH} and α_{IG} vs. α_{II} scores for an individual α_{IG} residue were added to yield a final score of 0 to 6. Residue identity in all three proteins produced a score of 6; pairing of an α_{IG} residue with unrelated amino acids in both alignments produced a score of 0. Exons 14, 16, 26, 35 and 38 had no apparent α_{IH} or α_{II} homologues; these residues are uncolored. Exon 36 and the C-terminal half of exon 8 had only α_{IH} homologues and exon 34 had only an α_{II} homologue; the maximum possible similarity score for these regions is 3. Splice sites, extracellular cysteines and potential *N*-glycosylation and phosphorylation sites identified with PROSITE are indicated by the appropriate symbols. Symbol colors have the following meanings: black – conserved among all human α_1 subunits, purple – conserved within 3 aa residues in the multiple sequence alignment of all human α_1 subunits, blue – conserved among the human ABE and GHI subfamilies, green – conserved among all human T α_1 subunits, brown – also present in human α_{IH} , orange – also present in human α_{IIB} , pink – unique to α_{IG} . PKA: cyclic-nucleotide-dependent protein kinase phosphorylation site, PKC: protein kinase C phosphorylation site, CKII: casein kinase II phosphorylation site, Tyr: tyrosine kinase phosphorylation site. One residue in ID1-2 was identified as a potential site for phosphorylation by both PKA and PKC.

Fig. 5 is a schematic diagram of the RNA processing leading to the 8 α_{II} variants.

DETAILED DESCRIPTION OF THE INVENTION

The human brain T calcium channel α_{1G} subunit gene, *CACNA1G*, has now been discovered to consist of 38 protein-coding exons. Alternative processing of the gene transcript allows this single gene to code for sixty-four distinct α_{1G} protein products. In Table 2, each exon or portion of an exon is listed. In Table 1, the component exons of individual splice variants are described. These two tables are sufficient for a complete description of the newly discovered compositions.

Table 1 lists the component exons of the 64 α_{1G} protein products. Only the missing portions of each variant are noted in the description; the symbol " Δ " denotes deletion of the exon following the symbol. Thus, variant 1 consists of all exons save 14, 25B, 26, 34, 35 and 38B; in other words, exons 1 – 13, 15– 24, 25A, 27 – 33, 36 – 37, 38A and 38C are concatenated to form the protein. The final column lists the number of aa residues in each variant.

Table 1. α_{1G} Splice Variants

Variant	Description	Exon 14	Exon 25B	Exon 26	Exon 34	Exon 35	Exon 38B	Length (aa)
1	$\Delta 14\Delta 25B\Delta 26\Delta 34\Delta 35\Delta 38B$	—	—	—	—	—	—	2164
2	$\Delta 14\Delta 25B\Delta 26\Delta 34\Delta 35$	—	—	—	—	—	+	2243
3	$\Delta 14\Delta 25B\Delta 26\Delta 34\Delta 38B$	—	—	—	—	+	—	2209
4	$\Delta 14\Delta 25B\Delta 26\Delta 34$	—	—	—	—	+	+	2288
5	$\Delta 14\Delta 25B\Delta 26\Delta 35\Delta 38B$	—	—	—	+	—	—	2212
6	$\Delta 14\Delta 25B\Delta 26\Delta 35$	—	—	—	+	—	+	2291
7	$\Delta 14\Delta 25B\Delta 26\Delta 38B$	—	—	—	+	+	—	2257
8	$\Delta 14\Delta 25B\Delta 26$	—	—	—	+	+	+	2336

5

10

15

20

25

30

35

40

45

50

55

9	$\Delta 14\Delta 25B\Delta 34\Delta 35\Delta 38B$	—	—	—	+	—	—	—	2182
10	$\Delta 14\Delta 25B\Delta 34\Delta 35$	—	—	—	+	—	—	+	2261
11	$\Delta 14\Delta 25B\Delta 34\Delta 38B$	—	—	—	+	—	+	—	2227
12	$\Delta 14\Delta 25B\Delta 34$	—	—	—	+	—	+	+	2306
13	$\Delta 14\Delta 25B\Delta 35\Delta 38B$	—	—	—	+	—	+	—	2230
14	$\Delta 14\Delta 25B\Delta 35$	—	—	—	+	—	+	+	2309
15	$\Delta 14\Delta 25B\Delta 38B$	—	—	—	+	—	+	—	2275
16	$\Delta 14\Delta 25B$	—	—	—	+	—	+	+	2354
17	$\Delta 14\Delta 26\Delta 34\Delta 35\Delta 38B$	—	—	+	—	—	—	—	2171

18	$\Delta 14\Delta 26\Delta 34\Delta 35$	—	+	—	+	2250
19	$\Delta 14\Delta 26\Delta 34\Delta 38B$	—	+	—	—	2216
20	$\Delta 14\Delta 26\Delta 34$	—	+	—	+	2295
21	$\Delta 14\Delta 26\Delta 35\Delta 38B$	—	+	—	—	2219
22	$\Delta 14\Delta 26\Delta 35$	—	+	—	+	2298
23	$\Delta 14\Delta 26\Delta 38B$	—	+	—	—	2264
24	$\Delta 14\Delta 26$	—	+	—	+	2343
25	$\Delta 14\Delta 34\Delta 35\Delta 38B$	—	+	—	—	2189
26	$\Delta 14\Delta 34\Delta 35$	—	+	—	+	2268

27	$\Delta 14\Delta 34\Delta 38B$	—	+	—	2234
28	$\Delta 14\Delta 34$	—	+	+	2313
29	$\Delta 14\Delta 35\Delta 38B$	—	+	—	2237
30	$\Delta 14\Delta 35$	—	+	—	2316
31	$\Delta 14\Delta 38B$	—	+	+	2282
32	$\Delta 14$	—	+	+	2361
33	$\Delta 25B\Delta 26\Delta 34\Delta 35\Delta 38B$	+	—	—	2187
34	$\Delta 25B\Delta 26\Delta 34\Delta 35$	+	—	—	2266
35	$\Delta 25B\Delta 26\Delta 34\Delta 38B$	+	—	+	2232

36	$\Delta 25B\Delta 26\Delta 34$	+	—	—	—	+	2311
37	$\Delta 25B\Delta 26\Delta 35\Delta 38B$	+	+	—	—	—	2235
38	$\Delta 25B\Delta 26\Delta 35$	+	—	+	—	+	2314
39	$\Delta 25B\Delta 26\Delta 38B$	+	—	+	+	—	2280
40	$\Delta 25B\Delta 26$	+	—	—	+	+	2359
41	$\Delta 25B\Delta 34\Delta 35\Delta 38B$	+	—	+	—	—	2205
42	$\Delta 25B\Delta 34\Delta 35$	+	—	+	—	+	2284
43	$\Delta 25B\Delta 34\Delta 38B$	+	—	+	—	—	2250
44	$\Delta 25B\Delta 34$	+	—	+	—	+	2329

45	$\Delta 25B\Delta 35\Delta 38B$	+	—	+	2253
46	$\Delta 25B\Delta 35$	+	—	+	2332
47	$\Delta 25B\Delta 38B$	+	—	+	2298
48	$\Delta 25B$	+	—	+	2377
49	$\Delta 26\Delta 34\Delta 35\Delta 38B$	+	+	—	2194
50	$\Delta 26\Delta 34\Delta 35$	+	+	—	2273
51	$\Delta 26\Delta 34\Delta 38B$	+	+	—	2239
52	$\Delta 26\Delta 34$	+	+	+	2318
53	$\Delta 26\Delta 35\Delta 38B$	+	+	—	2242

54	$\Delta 26\Delta 35$	+	—	+	2321
55	$\Delta 26\Delta 38B$	+	+	—	2287
56	$\Delta 26$	+	+	+	2366
57	$\Delta 34\Delta 35\Delta 38B$	+	+	—	2212
58	$\Delta 34\Delta 35$	+	—	+	2291
59	$\Delta 34\Delta 38B$	+	+	—	2257
60	$\Delta 34$	+	+	+	2336
61	$\Delta 35\Delta 38B$	+	+	—	2260
62	$\Delta 35$	+	+	+	2339

5

10

15

20

25

30

35

40

45

50

55

2305	2384
—	+
+	+
+	+
+	+
+	+
+	+
Δ38B	full
63	64

For each exon, the nucleotide sequence and the corresponding amino-acid (aa) sequence are listed in single-letter IUPAC code. Lower case letters in the aa sequences indicate that only two nucleotides of the codon belong to the exon (the codon is interrupted). A dash indicates a stop codon.

Table 2.

(SEQ ID NOs: 1 and 82) Exon 1 (constitutive)

atggacgaggaggaggatggagcgggcccggaggagtcgggacagccccggagcttcacgcggtcaa
cgacctgtcgggggcccgggcccgggcccgggtcagcagaaaaggaccgggcagcgcggact
ccgaggcggagggggtgccgtaccggcgctggccccgggtggtttcttctacttgagccaggacagc
cgccccgggagctggtgtctccgcacggtctgtaaccc

MDEEEDGAGAEESGQPRSPMRLNLSGAGGRPGPSAEKDPGSADSEAEGLPYPALAPVVFFYLSQDS
RPRSWCLRTVCNp

(SEQ ID NOs: 2 and 83) Exon 2 (constitutive)

ctggtttgagcgcatcagcatgttggtcatccttctcaactgcgtgacctgggcatgtccggccat
gcgaggacatcgctgtgactcccagcgctgccggatcctgcag

WFERISMLVILLNCVTLGMPFCEDIACDSQRCRILQ

(SEQ ID NOs: 3 and 84) Exon 3 (constitutive)

gcctttgatgacttcacatttgccttctttgccgtggagatggtggtgaagatggtggccttgggcat
ctttgggaaaaagtgttacctgggagacacttgaaccggcttgacttttcatcgatcgcagg

AFDDFIFAFFAVEMVVKMVALGIFGKKCYLGDTWNRLDFFIVIAg

(SEQ ID NOs: 4 and 85) Exon 4 (constitutive)

gatgctggagtactcgctggacctgcagaacgtcagcttctcagctgtcaggacagtcggtgtgctgc
gaccgctcagggccattaaccgggtgccca

MLEYSLDLQNVSFSAVRTVRVLRPLRAINRVP

(SEQ ID NOs: 5 and 86) Exon 5 (constitutive)

gcacgcgcacacctgtcacgttgcgtggatacgcgtgcccatgctgggaacgtcctgctgctctgc
ttcttctgtcttctcatcttcggcatcgctcggtccagctgtgggcagggtgcttcggaaccgatg
cttcctacctgagaatttcagcct

SMRILVTLLDLTLPMLGNVLLCFFVFFIFGIVGVQLWAGLLNRNRCFLPENFS1

5 (SEQ ID NOs: 6 and 87) Exon 6 (constitutive)

ccccctgagcgtggacctggagcgtattaccagacagagaacgaggatgagagccccttcactctgct
cccagccacgcgagaaacggcatgcggtcctgcagaagcgtgccacgctgcgcgggacggggcggt
ggccccacttgcggtctggactatgaggcctacaacagctccagcaacaccactgtgtcaactggaa
10 ccagtactacaccaactgctcagcgggggagcacaaccccttcaagggcgccatcaactttgacaaca
ttggctatgctggatcgccatcttcag

PLSVDLERYQ TENEDESP FICSQPRENGMRSCRSVPTLRDGGGGPPCGLDYEAYNSSNTTCVNWN
15 QYYTNC SAGEHNPFKGA INFDNIGYAWIAIFQ

15 (SEQ ID NOs: 7 and 88) Exon 7 (constitutive)

gtcatcacgctggagggtgggtcgacatcatgtactttgtgatggatgctcattccttctacaattt
20 catctacttcatcctcctcatcate

VITLEGWVDIMYFVMDAHSFYNFYIFILLII

25 (SEQ ID NOs: 8 and 89) Exon 8 (constitutive)

gtgggctccttcttcatgatcaacctgtgcctgggtggtgattgccacgcagttctcagagaccaagca
25 gcggaagaccagctgatcgaggagcagcgtgtcggttctctgccaacgcagcaccctggctagct
tctctgagcccgccagctgctatgaggagctgctcaagtacctggtgtacatccttcgtaaggcagcc
cgcaggctggctcaggtctctcgggcagcaggtgtcggggtgggctgctcagcagcccagcaccct
cgggggccaggagaccagcccagcagcagctgctctcgtcccaccgcgcctatccgtccaccacc
30 tgggtgcaccaccaccaccaccatcaccaccactaccacctgggcaatgggacgctcaggccccccgg
gccagcccggagatccaggacagggatgccaatgggtcccgcaggctcatgctgccaccaccctcgac
gcttgccctctccggggccccccctgggtggcgagagctctgtgcacagcttctaccatgccgactgcc
acttagagccagtcctgctgcaggcgccccctcccagggtccccatctgaggcatccggcaggactgtg
35 ggcagcggaaggtgtatcccaccgtgcacaccagccctccaccggagacgctgaaggagaaggcact
agtagaggtgggtgccagctctgggcccccaaccctcaccagcctcaacatcccaccgggcccctaca
gctccatgcacaagctgctggagacacagagtacag

VGSFFMINLCLVVIATQFSETKQRESQLMREQRVFLSNASTLASFSEPGSCYEELLKYLVIILKAA
40 RRLAQVSRAGVRVGLSSPAPLGGQETQPS SCSRSRRLSVHHLVHHHHHHHHHYHLGNGTLRAPR
ASPEIQDRDANGSRRLMLPPPSTPALSGAPPGAESVHSFYHADCHLEPVRQAPPPRSPSEASGRTV
GSGKVIPTVHTSPPPETLKEKALVEVAASSGPPTLTSLNIPGPYSSMHKLETTQST

45 (SEQ ID NOs: 9 and 90) Exon 9 (constitutive)

gtgctgcacaaagctcttgcaagatctccagcccttgcttgaaagcagacagtgagcctgtggtcca
gacagctgcccctactgtgccccggcggggagggaggtggagctcgccgaccgtgaaatgcctga
50 ctgagacagcgaggcagtttatgagttcacacaggatgccagcagcagcactccgggacccccaca

5 gccggcggaacaggagcctgggcccagatgcagagcccagctctgtgctggccttctggaggctaatac
tgtgacaccttccgaaagattgtggacagcaagtactttggccgggaatcatgatcgccatcctggg
caacacactcagcatgggcatcgaataccacgagcag

10 gACQSSCKISSPCLKADSGAGPDCPYCARAGAGEVELADREMPDSDSEAVYEFTQDAQHSDLRDPH
SRRQRSGLGPDAEPSSVLAFLWRLICDTFRKIVDSKYFGRGIMIAILVNTLSMGIEYHEQ

(SEQ ID NOs: 10 and 91) Exon 10 (constitutive)

15 cccgaggagcttaccacgcccctagaaatcagcaacatcgctcttcaccagcctctttgccctggagat
gctgctgaagctgcttgtgtatggctccctttggctacatcaagaatccctacaacatcttcgatggg
tcattgtggtcatcag

PEELTNALEISNIVFTSLFALEMLLKLIVYGPFGYIKNPYNIFDGVIVVIS

20 (SEQ ID NOs: 11 and 92) Exon 11 (constitutive)

cgtgtgggagatcgtgggcccagcagggggcgccgtgtcggtgctgcggaccttccgcctgatgcgtg
tgctgaagctgggtgcgcttctgcgcgctgcagcggcagctgggtgctcatgaagaccatggac
aacgtggccaccttctgcatgctgcttatgctcttcattcttcattcttcag

25 VWEIVGQGGGLSVLRTFRIMRVLKLVRFLPALQRQLVVLMTMDNVATFCMLLMFLIFIFIS

(SEQ ID NOs: 12 and 93) Exon 12 (constitutive)

30 catcctgggcatgcatctcttcggctgcaagtttgctctgagcgggatggggacaccttccagacc
ggaagaattttgactccttgcctgctggccatcgctcaatgctcttcag

ILGMHLFGCKFASERDGDITLDRKNFDSLWAIIVTVFQ

(SEQ ID NOs: 13 and 94) Exon 13 (constitutive)

35 atcctgaccaggaggactggaacaaagtcctctacaatggtatggcctccacgtcgtcctgggcggc
cctttatttcattgcccctcatgaccttcggcaactacgtgctcttcaatttgctgggtcgccattctgg
tggagggtctccaggcggag

40 ILTQEDWNKVLNCHASTSSWAALYFIALMTFCNIVLPNLLVAILVECPQAE

(SEQ ID NOs: 14 and 95) Exon 14 (variable)

45 gaaatcagcaaacgggaagatgcgagtgacagttaagctgtattcagctgcctgtcgactcccaggg
g

EISKREDASGQLSCIQLPVDSQG

(SEQ ID NOs: 15 and 96) Exon 15 (constitutive)

50

55

5 ggagatgccacaagtccgaatcagagcccgatttcttctcaccagcctggatggatggggacag
gaagaagtgttgccct

GDANKSESEPDFFSPSLDGDGDRKRCLA

10 (SEQ ID NOs: 16 and 97) Exon 16 (constitutive)

tggtgtccctgggagagcaccggagctgcggaagagcctgtgccgcctctcatcatccacacggcc
gccacacccatgtcgtgccaagagcaccagcagggcctggcgagggcgtgggccctgcgtcgcg
ccgcaccagcagcagcgggtcggcagagcctggggcgggcccacgagatgaagtcaccg

15 1VSLGHEPFLRKSLPLLIHTAATPMSLPKSTSTGLGEALGPASRRRTSSSGSAEPGAAHEMKSP

(SEQ ID NOs: 17 and 98) Exon 17 (constitutive)

20 cccagcgccccagctctccgcacagccctggagcgtgcaagcagctggaccagcagcgctccag
ccggaacagcctcgccgtgcacccagcctgaagcggagaagcccaagtggagagcggcggtccctgt
tgtcgggagaaggccaggagagccaggatgaagaggagagctcagaagaggagcgggccagccctgcg
ggcagtgaacctcgccacaggggtccctggagcgggagccaagagtcccttgacctgccagacac
actgcaggtgccagggtgcactgcactgccagtggcgagggtctgtctctgagcaccaggactgca
25 atggcaagtgcgttcagggcgcctggccggggcctgcggcctgatgacccccactggatggggat
gacgccgatgacgagggaacctg

30 PSARSSPHSPWSAASSWTSRRSRNSLGRAPSLKRRSPSGERRSLLSGEGQESQDEESSEERASPA
GSDHRHRGSLEREAKSSFDPDLQVPLHRTASGRGSASEHQDCNCKSASGRLARALRPDDPPLDGD
DADDEGNL

(SEQ ID NOs: 18 and 99) Exon 18 (constitutive)

35 agcaaggggaacgggtccgcgcgtgatccgagcccgactccctgcctgctgcctcgagcgagactc
ctggtcagcctacatcttccctctcagtcag

SKGERVRAWIRARLPACCLERDSWSAYIFPPQSR

(SEQ ID NOs: 19 and 100) Exon 19 (constitutive)

40 gttccgcctcctgtgtcaccggatcatcaccacaagatgttcgaccacgtggtccttgtcateatct
tccttaactgcataccatcgccatggagcgccccaaaattgacccccacagcgt

FRLLCHRIITHKMFHDHVLVIIFLNCITIAMERPKIDPHSA

45 (SEQ ID NOs: 20 and 101) Exon 20 (constitutive)

gaacgcattctcctgacctctccaattacatcttcaccgcagctcttctggtgaaatgacagtga
g

50

55

5

ERIFLTLSNYIFTAVFLAEMTVK

(SEQ ID NOS: 21 and 102) Exon 21 (constitutive)

10

gtggtggcaactgggctggtgcttcggggagcaggcgctacctgcggagcagttggaacgtgctggacgg
gctgttggtgctcatctccgtcatcgacattctggtgtccatggtctctgacagcggcaccaagatcc
tgggcatgctgagggtgctgcggctgctgcggaccctgcgcccgctcag

VVALGWCFCGEQAYLRSSWNVLGGLLVLSVIDIILVSMVSDSGTKILGMLRVLRLRLRLRLRL

15

(SEQ ID NOS: 22 and 103) Exon 22 (constitutive)

ggatgatcagccggcgaggggctgaagctggtggtggagacgtgatgtcctcactgaaacccatcg
gcaacattgtagtcatctgctgtgccttcttcatcattttcgcatcttgggggtgcag

20

VISRAQGLKLVVETLMSLKPIGNIVVICCAFFIIFGILGVQ

(SEQ ID NOS: 23 and 104) Exon 23 (constitutive)

ctcttcaaagggaagtttttcgtgtgccagggcgaggataccaggaacatcaccaataaatcgactg
tgccgagggcagttaccggtgggtccggcacaagtacaactttgacaaccttggccag

25

LFGKGFVCQGEDTRNITNKSDCAEASRWRHXYNFDNLQ

(SEQ ID NOS: 24 and 105) Exon 24 (constitutive)

gccctgatgtccctgttcgttttggcctccaaggatggttgggtggacatcatgtacgatgggctgga
tgctgtgggcgtggaccagcag

30

ALMSLFVLASKDGVVDIMYDGLDAVGVDQ

(SEQ ID NOS: 25 and 106) Exon 25A (constitutive)

cccatcatgaaccacaacccctggatgctgctgtacttcatctcgttcctgctcattgtggccttctt
tgtcctgaacatgtttgtgggtgtggtgggagaactccacaagtgtcggcagcaccaggagggaag
aggaggcccgccggcgggaggagaagcgcctacgaagactggagaaaaagagaagga

40

PIMNHNFWMLLYFISFLIVAFVFLNMFVGVVVENFHKRQHQQEEEEARRREEKRLRLLEKKRR

(SEQ ID NOS: 26 and 107) Exon 25B (variable)

gtaaggagaagcagatggctg

45

BKEKQMA

(SEQ ID NOS: 27 and 108 and 162) Exon 26 (variable)

atctaagtctggacgatgtaattgcttcggcagctcagccagcgtgcgtcag

50

55

5 nLMLDDVIASGSSASAAS (when follows exon 25A)
dLMLDDVIASGSSASAAS (when follows exon 25B)

(SEQ ID NOs: 28 and 109 and 163) Exon 27 (constitutive)
10 aagccagtgcaaaccttactactccgactactcccgttcgggtcctcgccaccacttgccacc
agccactacctggacctcttcacacaggtgtcatcggtgaacgtggtcaccatggccatggagca
ctaccagcagccccag

15 eAQCKPYYSYSDYSRFRLLVHHLCTSHYLDLFTIGVIGLNVVTMAMEHYQQPQ (when it follows
exon 25B or exon 26)

kAQCKPYYSYSDYSRFRLLVHHLCTSHYLDLFTIGVIGLNVVTMAMEHYQQPQ (when it follows
exon 25A)
20 (SEQ ID NOs: 29 and 110) Exon 28 (constitutive)
attctggatgaggtctctgaagatctgcaactacatcttcactgtcatctttgtcttgagtcagttt
caaacttggtgaccttggtttcgtcggttcttcaggagag

25 ILDEALKICNYIFTVIFVLESVFKLVAFGRFRFPQDr

(SEQ ID NOs: 30 and 111) Exon 29 (constitutive)
gtggaaccagctggacctggccattgtgctgctgtccatcatgggcatcacgctggaggaaatcgagg
30 tcaacgcctcgctgcccatcaaccccaccatcatccgcatcatgaggtgctgctgagcattgcccgag

WNQLDLAIVLLSIMGITLEEIEVNASLPINPTIIRIMRVLRIAR

(SEQ ID NOs: 31 and 112) Exon 30 (constitutive)
35 tgetgaagctgctgaagatggctgtgggcatgccccgctgctggacacggtgatgcaggccctgccc
cag

vLKLLKMAVGMRALLDTVMQALPQ

40 (SEQ ID NOs: 32 and 113) Exon 31 (constitutive)
gtggggaacctgggacttctcttcatgttgtgttttcatctttgcagctctggcgctggagctctt
tgagacctgg

45 VGNLGLLFHLLFFIFAALGVELFGDL

(SEQ ID NOs: 33 and 114) Exon 32 (constitutive)
agtgtgacgagacacacccctgtgagggcctggcgctcatgccaccttcggaactttggcatggcc
50 ttccataacctcttccgagctctccacaggtgacaattggaatggcattatgaag

5 eCDETHPCEGLGRHATFRNFGMAFLTLFRVSTGDNWNGIMK

(SEQ ID NOS: 34 and 115) Exon 33 (constitutive)

10 gacaccctccgggactgtgaccaggagtcacacacgggtcatctcgctatctactttgt
gtccttcgtgctgacggcccagttcgtgctagtcacgtggtgatcgccgtgctgatgaagcacctgg
aggagagcaacaaggaggccaaggaggagccgagctagaggctgagctggagctggagatgaagacc
ctcagccccagccccactcgccactgggcagcccccttctctggcctggggtcgagggccccgacag
15 ccccgacagcccaagcctggggctctgcaccagcgccacgcgagatcagcctcccacttttccc
tggagcaccacag

DTLRDCDQESTCYNTVISPIYFVSFVLTAQFVLNVVIAVLMKHLEESNKEAKEAELEAELEEMKT
LSPQPHSPLGSPFLWPGVEGPDSPDSPKPGALHPAAHARSASHFSLEHPT

20 (SEQ ID NOS: 35 and 116) Exon 34 (variable)

gacaggcagctgtttgacaccatattccctgctgatccagggtccctggagtgggagctgaagctgat
ggacgagctggcaggccaggggggcagccctctgccttcccttctgccccagcctgggaggtccg
25 acccacag

DRQLFDTISLLIQGSLEWELKLMDLAGGGQPSAFPSAPSLGGSDPQ

(SEQ ID NOS: 36 and 117) Exon 35 (variable)

30 atccctctagctgagatggaggctctgtctctgacgtcagagattgtgtctgaaccgtcctgctctct
agctctgacggatgactctttgctgatgacatgcacacactcttacttagtgccttgagagcaat

IPLAEMEALSLTSEIVSEFSCSLALTDDSLPDDMHTLLLSALESN

(SEQ ID NOS: 37 and 118) Exon 36 (constitutive)

35 atgcagccccacccacggagctgccaggaccagacttactgactgtgcggaagtctggggtcagccg
aacgcactctctgcccaatgacagctacatgtgtcgcatgggagcactgccgaggggccccctgggac
acaggggctgggggtccccaaagtcagtcag

40 MQPHTTELPGPDLLTVRKSGVSRTHSLPNDSYMCRHGSTAECPLGHRGWGLPKAQS

(SEQ ID NOS: 38 and 119) Exon 37 (constitutive)

45 gtcctgtctgtccgttcactcccagccagcagataccagctacatcctgcagcttcccaaagatgca
cctcatctgtccagccccacagcggcccaacctggggcaccatcccaaaactgccccaccaggacg
ctcccccttggtcagaggccactcaggcgccag

gSVLSVHSQPADTSYILQLFKDAPHLLQPHSAPTWGTIPKLPPGRSPLAQRPLRRQ

50 (SEQ ID NOS: 39 and 120) Exon 38A (constitutive)

gcagcaataaggactgactccttgagcttcagggtctgggcagccgggaagacctgctggcagag

AAIRTDSLDVQCLGSREDLLAE

(SEQ ID NOs: 40 and 121) Exon 38B (variable)

gtgagtgggccccccccccctggccccggcctactctttctggggccagtcaagtaccaggcaca
gcagcactcccgagccacagcaagatctccaagcacatgaccccgccagccccctgcccaggccag
aaccctaactggggcaaggccctccagagaccagaagcagcttagagtggacacggagctgagctgg
atttcaggagacctcctgccccctggcgccag

VSGFSPPLARAYSFWGQSTQAQQHSRSHSKISKHMTTPAPCPGPEPNWKGPPETRSSLLEDTLSW
ISGDLPPGGQ

(SEQ ID NOs: 41 and 122) Exon 38C (constitutive)

gaggagcccccatccccacgggacctgaagaagtgtacagcgtggaggccagagctgccagcggcctacgtc
tctattttattaaattaattgaatctagta

EEPPSPRDLKKCYSEVAQSCQRRPTSWLDEQRRHSIAVSCLDGSGQPHLGTDPNLGGQPLGGPGSRP
KKKLSPPSITIDPPESQGFRTPPSPGICLRRRAPSSDSKDPLASGPPDSMAASPSPKDVLSSLGLSS
DPADLDP-

(SEQ ID NO: 42) Exon 38D (variable)

tatgcgggatgtacgacatcttctgactgaagagactgtttccttctacttttatgtgtctcagaat
atctttgaggcgaaggcgtctgtctcttggtatcttaacctaaataacagtctagttatattccct
cttcttgcaaaagcacaagctgggacgcgagcacattgcagccccaacggtggcccatcttcagcgga
gagcgagaaccattttgaaactgtaagttaactatcttttcttaacctcgtcatctttctgt
agggaaaaaaaaaagaaaaaagaaaaatgagattttacaagtgaatggaaccttttatatacat
acatacatatctatctatctatctatataataaaataaagtaattttcctaataaaaa

Non-coding

The calcium channel α_{11} subunit gene, *CACNA11*, consists of 37 protein-coding exons. Alternative processing of the gene transcript allows this single gene to code for eight distinct α_{11} protein products. In Table 4, each exon or portion of an exon is listed. In Table 3, the component exons of individual splice variants is described. These two tables are sufficient for a complete description of composition. The presumed RNA processing mechanisms giving rise to these variants are discussed below.

Table 3 lists the composition of the 8 α_{II} protein products. Only the missing portions of each variant are noted in the description; the symbol " Δ " denotes deletion of the exon following the symbol. Thus, variant 1 consists of all exons save 9, 33A and 36B; in other words, exons 1 – 8, 10 – 32, 33B, 34 – 35, 36A and 37 are concatenated to form the protein. The final column lists the number of aa residues in each variant.

Table 3. α_{II} Splice Variants

Variant	Description	Exon 9	Exon 33A	Exon 36B or 37	Length (aa)
1	$\Delta 9\Delta 33A\Delta 36B$	Δ	Δ	37	2175
2	$\Delta 9\Delta 33A\Delta 37$	Δ	Δ	36B	1968
3	$\Delta 9\Delta 36B$	Δ	+	37	2188
4	$\Delta 9\Delta 37$	Δ	+	36B	1981
5	$\Delta 33A\Delta 36B$	+	Δ	37	2210
6	$\Delta 33A\Delta 37$	+	Δ	36B	2003
7	$\Delta 36B$	+	+	37	2223
8	$\Delta 37$	+	+	36B	2016

For each exon, the nucleotide sequence and the corresponding amino-acid (aa) sequence are listed in single-letter IUPAC code. Lower case letters in the aa sequences indicate that only two nucleotides of the codon belong to the exon (the codon is interrupted). A dash indicates a stop codon.

TABLE 4(SEQ ID NOs: 43 and 123) Exon 1 (constitutive)

atggctgagagcgctccccgccctcctcatctgcagcagccccagcgcgtgagccaggagtaccac
ggagcagcccgacccccggagcccccatcctccccgccaggcctggaggagcctctggatggagctg
atcctcatgtccacacccagacctggcgctattgccttcttctgctgcgacagaccaccagcccc
cggaactggtgcatcaagatggtgtgcaacc

MAESASPPSSSAAAPAAEPGVTTTEQPGPRSPSSPPGLEEPLDGADPHVPHDLAPIAFFCLRQTTSP
RNWCIRKVCNp

(SEQ ID NOs: 44 and 124) Exon 2 (constitutive)

gtggtttgaatgtgtcagcatgtgtgatcctgctgaactgcgtgacacttggcatgtaccagccgt
gcgacgacatggactgcctgtccgaccgctgcaagatcctgcag

WFECVSMVLVILLNCVTILGHYQPCDDMDCLSDRCKILQ

(SEQ ID NOs: 45 and 125) Exon 3 (constitutive)

gtctttgatgaattcatctttatcttcttggccatggagatggtgctcaagatggtggccctggggat
ttttggcaagaagtgtacctcggggacacatggaaccgctggatttcttcatcgtcatggcagg

VFDDFIFIFFAMEMVLKMHVALGIFGKKCYLGDTWNRLDFFIVMg

(SEQ ID NOs: 46 and 126) Exon 4 (constitutive)

gatggtcgagtactccttgaccttcagaaacatcaacctgtcagccatccgcaccgtgcgcgtcctga
ggccctcaaagccatcaaccgctgcca

MVEYSLDLQNINLSAIRTVRVLRLKAINRVP

(SEQ ID NOs: 47 and 127) Exon 5 (constitutive)

gtatcggtatcctggtgaacctgctcctggacacactgccatgctgggaatgtcctgctgctctgc
ttctttgtcttctcatcttggcatcataggtgtgcagctctggcgggcctgctgcgtaaccgctg
cttcttgaggagaacttaccat

aMRILVNLLDTPMLGNVLLCFFVFFIFGIIGVQLWAGLLRNRCFLEENFTI

5 (SEQ ID NOs: 48 and 128) Exon 6 (constitutive)

acaaggggatgtggccttgcctccatactaccagcggaggaggatgatgagatgcccttcatctgct
ccctgtcgggcgacaatgggataatgggctgccatgagatcccccgctcaaggagcagggcogtgag
tgcgtcctgtccaaggacgacgtctacgactttggggcgggcgccaggacctcaatgccagcgccct
ctgtgtcaactggaaccgttactacaatgtgtgccgcacgggcagcgccaacccccacaaggtgccca
tcaactttgacaacatcggttatgcttggttgcctctccag

QGDVALPPYYQPEDEMPFICSLSGDNGIMGCHEIPPLKEQGREGCLSKDDVYDFGAGRQDLNASGL
CVNWNRYYNVCRTGSANPHKGAINFDNIGYANIVIFQ

15 (SEQ ID NOs: 49 and 129) Exon 7 (constitutive)

gtgatcactctggaagcctgggtggagatcatgtactacgtgatggatgctcactccttctacaactt
catctacttcatcctgcttatcata

20 VITLEGWVEIMYYVMDAHSFYFIYFILLII

(SEQ ID NOs: 50 and 130) Exon 8 (constitutive)

gtgggtcctctcttcatgatcaacctgtgcctcgttgcatagcgacccagttctcgagaccaagca
acgggagcacccgctgatgctggagcagcggcagcgctacctgtcctccagcacgggtggccagctacg
ccgagcctggcgactgctacgaggagatctccagtatgtctgcacatcctgcgcaaggccaagcgc
cgcgccctgggctctaccaggccctgcagagccggcgccaggccctgggccccggaggccccggcccc
cgccaaacctgggccccacgccaaggagccccggcactacc

30 VGSFFMINLCLVVIATQFSETQREHRLMLEQRQRYLSSSTVASIAEPGDCYEEIFQYVCHILRKAKR
RALGLYQALQSRRLGPEAPAPAKPGPHAKEPRHY

(SEQ ID NOs: 51 and 131) Exon 9 (variable)

35 atgggaagactaagggctcagggagatgaaggagacatctcggaagccgcattgccagactttgcct
gggcctgcctccctggaaatgatcactcgggaagag

hgkTKGQGDEGRHLGSRHCQTLHGFPASPGNDHSGR

40 (SEQ ID NOs: 52 and 132 and 164) Exon 10 (constitutive)

agctgtgcccgaacatagccccctggatgcgacgccccacacctggtgcagcccatccccgccacg
ctggcttccgatcccgccagctgcccttgcctgccagcatgaggacggccggcgccctcgggcctggg
cagcaccgactcgggccaggagggtcgggctccgggagctccgctggtggcgaggacgaggcggtg
gggacggggcccgagcagcaggagcggagcctcctcagaactggggaaggaggaggaggaggagg
caggcggtggggcggtctggctgtcggggatgtgtggcgggagacgcgagccaagctgcggcgcat
cgtggacagcaagtacttcaaccggggcatcatgatggccatcctggtcaacaccgtcagcatgggca
tcgagcaccacgagcag

5 eLCPQHSPLDATPHTLVQPIPATLASDPASCPCCQHEDGRRPSGLGSTDGQEGSGSGSSAGGEDEAD
GDGARSSSEDGASSELGKEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMG
IEHHEQ (when it follows exon 9)

10 qLCPQHSPLDATPHTLVQPIPATLASDPASCPCCQHEDGRRPSGLGSTDGQEGSGSGSSAGGEDEAD
GDGARSSSEDGASSELGKEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMG
IEHHEQ (when it follows exon 8)

(SEQ ID NOs: 53 and 133) Exon 11 (constitutive)

15 ccggaggagctgaccaacatcctggagatctgcaatgtggtcttcaccagcatgtttgccctggagat
gatcctgaagctggctgcatttgggtctctcgactacctgctgaaccctacaacatcttcgacagca
tcattgtcatcatcag

PEELTNILEICNVFTSMFALEMILKLAAPGLFDYLRNPYNIFDSIIIVII

20 (SEQ ID NOs: 54 and 134) Exon 12 (constitutive)

catctgggagatcgtggggcaggcggacgggtgctcgggtgctgcggaccttcgggtgctgcgcg
tgctgaaactggtgcgttcctgacctgccctgcggcgccagctcgtggtgctcatgaagaccatggac
aacgtggccacctctgcatgctgctcatgctcttcattcttcattctcag

IWEIVGQADGGLSVLRTFRLRLVRLVRFMPALRRQLVVLMTMDNVATFCMLLMLFIFIF

(SEQ ID NOs: 55 and 135) Exon 13 (constitutive)

30 catccttgggatgcataatttttggtgcaagttcagcctccgcacggacactggagacacggtgcccg
acaggaagaacttcgactccctgctgtgggccatcgtcactgtgttcag

ILGMHIFGCKFSLRTDTGDTVDRKNFDSLLWAIIVTFQ

35 (SEQ ID NOs: 56 and 136) Exon 14 (constitutive)

atcctcaccacaggaggactggaacgtcgttctctacaatggcatggcctccacttctccctgggcctc
cctctactttgtcgccctcatgaccttcggcaactatgtgctcttcaacctgctggtggccatcctgg
tggagggttcacaggcggag

40 ILTQEDWNVLYNGHASTSPWASLYFVALMTFCNYVLFNLLVAILVEGFQAE

(SEQ ID NOs: 57 and 137) Exon 15 (constitutive)

45 ggtgacgccaatcgtcctactcggacgaggaccagactcatccaacatagaagagtttgataagct
ccaggaaggcctggacagcagcggag

GDANRSYSDQSSSNIEFDKLQEGLDSSG

(SEQ ID NOs: 58 and 138) Exon 16 (constitutive)

50

55

5 atcccaagctctgcccataccccatgaccccccaatgggcacctggaccccagctctccactgggtggg
cacctaggctcctgctggggtgctgggacctgcccccgactctcactgcagccggaccccatgctggt
ggccctgggctcccgaaagagcagtgatgtctctagggaggatgagctatgaccagcgctccctg

10 dPKLCPIPMTPNGHLDPSLPLGGHLPAGAAGPAPRLSLQDPMLVALGSRKSSVMSLGRMSYDQRL
(SEQ ID NOS: 59 and 139) Exon 17 (constitutive)

15 tccagctcccgagctcctactacgggcatggggccgcagcgccgctgggcccagccgctcctccag
ctggaacagcctcaagcacaagccgcgctcgccggagcatgagtcctctctctgaggagcgccggg
gcccgcgccgggtctgcgaggttgcgcggacgagggccgcgcggccgcacccctgcacacccca
cacgcccaccacattcatcacgggccccatctggcgacccgccaccacccgcccggacgtgtc
cctcgacaacagggactcgttgacctggccgagctggtgcccgggtgggcccacccccgggccc
cctggaggcgccgaggccccggccccggccatgaggactgcaatggcaggatgccagcatcgccaaa
20 gacgtcttcaccaagatgggcgacccggggatcgccggaggatgaggagaaatcgactac

SSSRSSYYGPWGRSAAWASRRSSWNSLKHKPPSAEHESLLSAERGGGARVCEVAADGPPRAAPLHTP
HAHHIHHGPHLAHRHRHRTLSLDNRDSVDLAELVPAVGAHPRAAWRAAGPAPGHEDCNGRMPSTAK
DVFTKMGRDGRGEDEEEIDY

25 *(SEQ ID NOS: 60 and 140) Exon 18 (constitutive)*

acccctgtctcccgctccgcaagatgatcgacgtctataagcccactgggtcgagggtccgcgaaga
ctggctctgtctacctcttctctcccgagaacag

30 TLCFVRVKMIDVYKPDWCEVREDWSVYLFSPENr

(SEQ ID NOS: 61 and 141) Exon 19 (constitutive)

35 gttccgggtcctgtgtcagaccattattgcccacaaactcttcgactacgtcgtcctggccttcactt
ttctcaactgcacaccatcgccctggagcgccctcagatcgaggccggcagcacc

FRVLCQTIIAHKLFDYVVLAFIFLNCITIALERPQIEAGST

(SEQ ID NOS: 62 and 142) Exon 20 (constitutive)

40 gaacgcacatctttctaccgtgtccaactacatcttcacggccatcttcgtggcgagatgacattgaa
g

ERIFLTVSNYIFTAIFVGEMTLK

45 *(SEQ ID NOS: 63 and 143) Exon 21 (constitutive)*

gtagtctcgtgggctgtacttcggcgagcaggcgtacctacgcagcagctggaacgtgctggatgg
ctttcttgtcttcgtgtccatcatcgacatcgtggtgtccctggcctcagccggggagccaagatct
50 tgggggtcctccgagctcttgccggtcctgcgcacccctacgccccctgcg

5 VVSLGLYFGEQAYLRSSWNVLDFLVFVSIIDIVVSLASAGGAKILGVLRLRLRLTLRPLr
(SEQ ID NOs: 64 and 144) Exon 22 (constitutive)
tgatcatcagccggcgccggcctgaagctgggtggagacactcatctcctccctcaagcccatcg
10 gcaacatcgtgctcatctgctgtgccttcttcatcatctttggcatcctgggagtgag
VISRAPGLKLVVETLISSLKPIGNIVLICCAFFIIFGILGVQ
(SEQ ID NOs: 65 and 145) Exon 23 (constitutive)
15 ctcttcaagggcaagttctaccactgtctggcggtggacaccgcgaacatcaccaaccgctcggactg
catggccgccaactaccgctgggtccatcacaatacaacttcgacaacctgggcccag
LFRGKPHYHCLGVDTRNITNRSDCMAANYRWVHHKYNFDNLGQ
(SEQ ID NOs: 66 and 146) Exon 24 (constitutive)
20 gctctgatgtccctctttgtcctggcatccaaggatggtgggtgaacatcatgtacaatggactgga
tgctgttgctgtggaccagcag
ALMSLFVLASKDGVNIMYNGLDVAVDQQ
25 *(SEQ ID NOs: 67 and 147) Exon 25 (constitutive)*
cctgtgaccaaccacaaccctggatgctgctgtacttcatctccttctgctcatcgtcagcttctt
tgtgtctcaacatgtttgtgggtgctgtgggtgagaaacttccacaagtgcggcgagaccaggaggctg
30 aagaggcacggcggtgaggagaagcggtgcggcgctggagaagaagcgccgga
PVTNHNPMWLLYFISFLIVSFFVLNMFVGVVVENPHKCRQHQAEEARRREEKRLRRLEKKRR
(SEQ ID NOs: 68 and 148) Exon 26 (constitutive)
35 aggccagcggtgccctactatgccacctattgtcacaccggctgctcatccactccatgtgcacc
agccactacctggacatcttcatcaccttcatctgctcaacgtggtcaccatgtccctggagca
ctacaatcagcccag
40 KAQRLLPYATYCHTRLLIHSMTSHYLDIFITFIICLNVVMTSLHYNQPT
(SEQ ID NOs: 69 and 149) Exon 27 (constitutive)
tccctggagacagccctcaagtactgcaactatatgttcaccactgtctttgtgctggaggctgtgct
45 gaagctgggtgcatgttgctgaggcgcttcttcaaggaccg
SLETALKYCNYMFTTVFVLEAVLKLVAFLRRFFKDr
(SEQ ID NOs: 70 and 150) Exon 28 (constitutive)

5 atggaaccagctggacctggccattgtgctactgtcagtcacatgggcatcaccctggaggagatcgaga
tcaatgcggccctgcccataatcccaccatcatccgcatcatgagggttctgcgcattgcccag

WNQLDLAIVLLSVMGITLEEIEINAALPINPTIIRIMRVLRIAR

10 (SEQ ID NOs: 71 and 151) Exon 29 (constitutive)

tgctgaagctgttgaagatggccacaggaatgcggccctgctggacacgggtggtgcaagctttgccc
cag

vLKLLKMATGHRALLDTVVQALPQ

15 (SEQ ID NOs: 72 and 152) Exon 30 (constitutive)

gtgggcaacctgggacctctctctcatgctgctctctctcatctatgctgctctcggggtggagctctt
tggaagctgg

20 VGNLGLLFMLFFIYAALGVLFGL

(SEQ ID NOs: 73 and 153) Exon 31 (constitutive)

25 tctgcaacgacgagaacctgctgcgagggcatgagccggcatgccaccttcgagaacctcgccatggcc
ttcttcacactcttccaggtctccacgggtgacaactggaacgggatcatgaag

VCNDENPCEGMSRHATFENFGMAFLTLFQVSTGDNWNGIMK

(SEQ ID NOs: 74 and 154) Exon 32 (constitutive)

30 gacacgctgctggactgcacccacgacgagcagctgcctgagcagcctgcagtttgtgtcgcct
gtacttcgtgagcttcgtgctcacgcgcagttcgtgctcatcaacgtggtggtggctgtgctcatga
agcaacctggacgacgacaacaggaggcgcaggaggacgcgagatggatgccgagctcgagctggag
atggcccatggcctggccctggcccgaggetgcctaccggctccccgggcgcctctggccgagggcc
35 gggagggggcggcgggggcgacaccgagggcggttgtgcggcgctgctactgcctgccag

DTLRDCTHDERSCSLQFVSPLYFVSFVLTAQFVLINVVAVLMKHLDDSNKRAQEDAEMDAELELE
MAHGLGPGPRLPTGSPGAPGRGPGGAGGGGDTGGGLCRRCYSPAQ

40 (SEQ ID NOs: 75 and 155) Exon 33A (variable)

gagaacctgtggctggacagcgtctctttaetcatcaag

ENLWLDVSLLIK

45 (SEQ ID NOs: 76 and 156) Exon 33B (constitutive)

gactccttgagggggagctgaccatcatcgacaacctgtcgggtccatcttccaccactactctc
gcctgccgggtgcaagaagtgtcaccacgacaagcaagag

50 DSLEGELTIIDNLGSGSIFHHYSSPAGCKKCHHDKQE

5

(SEQ ID NOS: 77 and 157) Exon 34 (constitutive)

gtgcagctggctgagacggaggccttctccctgaactcagacaggtcctcgtccatcctgctgggtga
cgacctgagtctcgaggacccacagcctgccacctggccgcaaagacagcaag

10

VQLAETAFSLNSDRSSSILLGDDLSLEDPTACPPGRKDSK

(SEQ ID NOS: 78 and 158) Exon 35 (constitutive)

15

ggtgagctggaccacctgagcccatgcgtgtgggagacctgggcgaatgcttcttcccttgcctc
tacggcgtctctcgccgatccagagaacttctgtgtgagatggaggagatcccatccaacctgtcc
ggtcctggctgaaacatgacagcagtcag

GELDPPEPMRVGDLGECFFPLSSTAVSPDPENFLCEMEEIPFNPVRSWLKHDSSQ

20

(SEQ ID NOS: 79 and 159) Exon 36A (constitutive)

caccccccaagtccttctccccggatgcctccagccctctcctgcccagccagcaggttcttcac
cctgcagtgtctgccagccagaaaggccagaaaaggcactggcactggaacctccccaagattgc
gctgcagggtcctgggcctctctgcggtcaccaagggtcaactgtacctctctccggcag

25

aPPSPFSPDASSPLLPMFAEFFHFAVSASQKGPKEGTGTGLPKIALQGSWASLRSPRVNCTLLRQ

(SEQ ID NOS: 80 and 160) Exon 36B (mutually exclusive with Exon 37)

gtaccgacacctcccaggccctagagcactggtctgtgggcaaggggcaggatctaagccaggcct

30

ggaagtccaagggactgggaggggaaggacccaaccaaggccgagggcaccaccgtgcaagggg
tttgggaacgctggggtgacgctgagactggaggggaggtggcactgggcccgatggagtggcg
gggctgggtcctggggacagcagagtgtggggaggacccaaggcgggtctggaaggccctgtga
tcctagcttgaggggaggggagagaggaggaggtactggaggttttgagggtggcggggtg

35

ctggcagtgaggagacacctgggtgctctgggtgggtgtgagtggggccttgattactaggaat
ggaggtgggagggcgggtctggtgatgagaagcctcgggctgcagggtccccgactggattgg
ccagggccacagccctcctaccacgggcacacagaggtctgaagcactgagggtccgctgtggg
ggtggggaatggggccgggcccgtcccacagtgagtcagttgattcactgggtgactgtctga

40

cccgctcacaccaggctgtgtgctctggcgggcaggacacaaactccctgcctgccgggctcactgt
ttagtctgagagtgaagctgcctgggtgcaggaggatgataacccaaataaa

VPTPPRP-

45

(SEQ ID NOS: 81 and 161) Exon 37 (mutually exclusive with exon 36B)

gccaccgggagcgacacgtcgtggacgcccagccagcctccgcccgcagcctgcagaccacgct

cgaggacagcctgacctgagcgacagccccggcgtgccctggggccgccgcgctgctccaggac

ccggggccggcctgtcccccgccgtcgcgcgcgctgagcctgcgcggccgggctcttcagcctg

50

cggggggtgcgggcgcacagcgacccacagcgggggtccaccagcccgggctgcaccacca

55

cgactccatggaccctcggacgagggggccggtggcgggggcgggggcgggcgagcagc
 actcggagaccctcagcagcctctcgtcacctccctcttctgcccgccgcccccgccgagcccc
 ggccctacgcccccgaggaagttcagcagcaccagcagcctggccgcccccgccgccccacgccgc
 cgccctggccccacggcctggcccgagccctcgtggggcgggaccgcagcaaggaccccccgcc
 gggcaccgctgccccggcctgggcccccttgccgcccccgccgcaaccgctccccggagagctggag
 ccgggagacgccccagcaagaggaagagatgagggcgagggggcccccgccgccccaccgcccgcc
 ccgtctcacctctcttacctcaggagccaggagcagacagcaatacttcgtccacacctgggatcgcg
 caggggccccgagggcacaggcgcccgacagccgggctgagcggagctctgggttagccaggcctgcgtg
 gcccatggtggccctccagtgcatacatatataatataatataatataatataatataatata
 tatatatatgtgtatacacacacacatagacagacatatatatatatattttttttttactgagag
 cttatgacttc
 ATGSDTSLDASPSSSAGSLQTTLEDSTLSDSPPRRALGPPAPAGPFRAGLSPAARRRLSLRGRGLFSL
 RGLRAHQSHSSGGSTSPGCTHDSMDPSDEGRGGAGGGGAGSEHSETLSSLSLTLFCPPPPPPAP
 GLTPARKFSSTSLAAPGRPHAAALAHGLARSPSWAADRSKDPGRAPLPMGLGPLAPPPQPLPGELE
 PGDAASKRRK-

RNA processing mechanisms

Figure 5 is a schematic diagram of the RNA processing leading to the 8 variants. The portion of the Figure above the scale bar represents the *CACNA1I* gene. The three sections of the gene involved in alternative processing are drawn to scale.

At the left, variable exon 9 (olive) is flanked by constitutive exons 8 (black) and 10 (purple). The black lines between exons represent introns.

In the middle, constitutive exon 32 is black. Exon 33 is divided into 2 parts, 39-nucleotide (nt) variable exon 33A (orange) and 108-nt constitutive exon 33B (blue).

At the right, exon 36 is divided into 2 parts, 197-nt constitutive exon 36A (black) and variable exon 36B (red), encoding seven aa before a stop codon. Constitutive exon 37 (green) encodes 214 aa before a stop codon.

Exons 1 – 7, 11 – 31 and 34 – 35 are not represented.

The blue and red lines and red arrow above and below the exons represent alternative RNA processing reactions.

Below the scale bar are representations of the 8 α_{11} protein products. The portions of the protein derived from exons 1 – 7, 11 – 31 and 34 – 35 are uncolored. Portions derived from the other exons are color-coded as in the gene map, above. Note that exon 36B encodes only 7 aa. The thin blue and red lines above the protein

5 products correspond to the lines around the gene map and represent the type of RNA processing reactions that resulted in the particular variant.

10 a. Alternative splicing of exon 9

5 Variants 1 – 4 result from the deletion of exon 9. In the blue reaction, splicing takes place between the donor 3' to exon 8 and the acceptor 5' to exon 10. Variants 5 – 8 result from RNAs subjected to the red reactions. In this case, two splicing reactions take place. The donor 3' of exon 8 and the acceptor 5' of exon 9 are joined as are the donor 3' of exon 9 and the acceptor 5' of exon 10. The portion encoded by exon 9 is retained.

10 b. Selection of the splice acceptor preceding exon 33A or 33B

20 Variants 1, 2, 5 and 6 result from the deletion of exon 33A. In the blue reaction, splicing takes place between the donor 3' of exon 32 and the acceptor internal to exon 33. Variants 3, 4, 7 and 8 result from RNAs subjected to the red reaction. In this case, splicing takes place between the donor 3' of exon 32 and the acceptor 5' of exon 33. The portion encoded by exon 33A is retained.

25 c. Processing of the 3' end

30 Variants 1, 3, 5 and 7 result from the deletion of exon 36B. In the blue reaction, splicing takes place between the donor internal to exon 36 and the acceptor 5' of exon 37. Exon 37 encodes the final 214 aa of the protein in these variants. Variants 2, 4, 6 and 8 result from RNAs subjected to the red reaction. In this case, the RNA is cleaved and polyadenylated just 3' of exon 36. In these variants, exon 36B encodes the final 7 aa of the protein.

35 Isolated and purified polypeptides or proteins, according to the present invention comprise at least about 10% by weight of a composition of proteins. Preferably the composition contains at least 25%, 50%, 75%, 85%, or 90% by weight of the particular polypeptide or protein. Any purification method can be applied, either to naturally expressing cells, such as neurons, or to cells which have been engineered to express a recombinant form of the polypeptide or protein. Purification methods known in the art which can be used without limitation include affinity chromatography, immunoprecipitation, immunoaffinity chromatography, molecular sieves, and ion exchange chromatography.

Non-naturally occurring variants which retain substantially the same biological activities as naturally occurring protein variants, such as calcium channel function, are also included here. Preferably, naturally or non-naturally occurring variants have amino acid sequences which are at least 85%, 90%, or 95% identical to the amino acid sequences shown in the SEQUENCE LISTING found at the end of the application. More preferably, the molecules are at least 98% or 99% identical. Percent identity is determined using the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 1. The Smith-Waterman homology search algorithm is taught in Smith and Waterman, *Adv. Appl. Math.* (1981) 2:482-489.

Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity can be found using computer programs well known in the art, such as DNASTAR software. Preferably, amino acid changes in secreted protein variants are conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.

It is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological properties of the resulting variant. Whether an amino acid change results in a functional calcium channel subunit protein or polypeptide can readily be determined by testing the altered protein or polypeptide in a functional assay.

Variants of the calcium channel subunit proteins disclosed herein include glycosylated forms, aggregative conjugates with other molecules, and covalent

5 conjugates with unrelated chemical moieties. Covalent variants can be prepared by
linking functionalities to groups which are found in the amino acid chain or at the N-
10 or C-terminal residue, as is known in the art. Variants also include allelic variants,
species variants, and muteins. Truncations or deletions of regions, particularly exons,
15 which do not affect functional activity of the proteins are also variants.

A subset of mutants, called muteins, is a group of polypeptides in which neutral
amino acids, such as serines, are substituted for cysteine residues which do not
15 participate in disulfide bonds. These mutants may be stable over a broader
temperature range than native proteins or have other beneficial changes in
20 physicochemical properties.

Any coding sequence can be used to generate a recombinant form of the protein
which results in the proper amino acids being used. However, the natural human
nucleic acid sequences are preferred. The coding sequence can be fused, for
25 example, to expression control sequences, signal sequences, and/or to other coding
sequences to form a fusion protein. All of the exons of a particular subunit can be
15 used in such constructs. Alternatively one or more isolated exons can be used.

Nucleic acids which are isolated and purified are separated from the rest of the
30 chromosome on which they reside in human cells. Preferably the particular nucleic
acid is the predominant molecular species in a composition. More preferably the
20 nucleic acid comprises at least 75%, 80%, 85%, 90%, or 95% of the molecular
species (including only nucleic acids) in the composition.

Degenerate polynucleotide sequences which encode amino acid sequences of the
35 proteins and variants, as well as homologous nucleotide sequences which are at least
65%, 75%, 85%, 90%, 95%, 98%, or 99% identical to the nucleotide sequences
40 25 shown in the Sequence Listing are also polynucleotide molecules of the invention.
Percent sequence identity is determined using computer programs which employ the
Smith-Waterman algorithm, such as the MPSRCH program (Oxford Molecular),
45 using an affine gap search with the following parameters: a gap open penalty of 12
and a gap extension penalty of 1.

30 Typically, homologous polynucleotide sequences can be confirmed by
hybridization under stringent conditions, as is known in the art. For example, using

the following wash conditions--2 x SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2 x SSC, 0.1% SDS, 50 °C once, 30 minutes; then 2 x SSC, room temperature twice, 10 minutes each--homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

The nucleic acid can be cloned into a vector, particularly an expression vector. Any suitable expression vector as is known in the art may be used without limitation. Host cells are preferably used which are human, although other host cells including yeast, bacteria, insect, plant and mammalian cells can be used. The cells can be selected for their desired properties. Typically these are selected for their interaction with a vector, or for a property which renders nucleic acids or proteins easily obtainable from the cells.

Host cells which express an α_1 subunit according to the present invention or an α_1 polypeptide can be used to test compounds or compositions for their possible beneficial effect for treating epilepsy. Thus, a test substance can be contacted with such a host cell and the calcium ion uptake by the cell can be measured. A test substance which blocks calcium ion uptake by the cell is identified as a candidate drug for treating or preventing epilepsy. Methods for measuring calcium uptake are known in the art, and any such method may be used for drug identification. See for example, Lee *et al.*, *J. Neuroscience* 19:1912-21, 1999.

The following examples are provided to demonstrate how the invention was made. However, the subject matter of the invention is not limited to any particular method of making the claimed polypeptides, proteins, vectors, and host cells.

EXAMPLES

Example 1

Analysis of sequence produced by the Human Chromosome 22 Sequencing Group at the Sanger Centre revealed putative exons of a T α_1 subunit gene in three overlapping clones of a human genomic DNA library mapping to 22q12.3-13.2: dJ1104E15 (AL022312), dJ206C7 (AL008716) and dJ172B20 (AL022319). *tblastn* alignment with the α_1 G (AF027984) or α_1 H (AF051946) amino-acid (aa) sequence

identified 26 exons; **FEX** analysis, another six; and inspection of upstream sequence, a candidate exon encoding the N-terminus. Potential polyadenylation signals were located with **POLYAH**. Putative exons were assembled into a provisional cDNA sequence and primers for polymerase chain reaction (PCR)-amplification of overlapping portions of the cDNA were designed with **OLIGO** (National Biosciences).

PCR screening of a multiple-tissue cDNA panel (Clontech #K14201) revealed brain as the most abundant cDNA source. Hence, human brain cDNA (Clontech #74001) served as template in subsequent PCRs. The predominant (and in some cases secondary) product of each PCR was recovered on a spin-column (Qiagen #28704) after agarose gel electrophoresis, eluted in water and submitted for sequencing. Exon boundaries were determined by comparison of the cDNA and genomic sequences; ambiguity was resolved by matching potential donors and acceptors to consensus sequences.

Fig. 1 shows 28 of the 49 overlapping PCR products (top) that contributed to the cDNA sequence. Also pictured are exon maps of the cDNA (middle) and the gene (bottom). *CACNA1I* consists of at least 37 exons distributed over at least 116,390 basepairs (bp). Most PCRs yielded a single product suggesting constitutive splicing of 33 exons (colored gray or black in the cDNA and genomic maps). Certain PCRs, however, yielded multiple products (interrupted black bars), indicative of alternative splicing. PCRs spanning the 105-nucleotide (nt) exon 9 (red), for example, yielded two products, (14 and +14; thus, exon 9 is a cassette exon subject to type A alternative splicing. Sequencing of PCR products spanning exon 33 revealed that exon 33 harbors an internal acceptor that leads to type C alternative splicing and deletion of 39 nt at the 5' end of the exon defined as exon 33A (orange).

Sequence analysis suggested the possibility of alternative 3' exons. Indeed, PCR-amplification of brain cDNA followed by sequencing showed two forms with substantially different 3' termini. In the first form, both exon 36A and 36B (green) are part of the mature mRNA. Exon 37 (blue) is presumably lost as a result of polyadenylation and cleavage at a site 686 bp downstream of the stop codon in exon 36B. In the second form, splicing between an alternative donor internal to exon 36

and the acceptor 5' of exon 37 leads to substitution of exon 36B with exon 37. The polyadenylation signal of exon 37 has not been identified.

Introns 2 – 8 and 11 – 35 are common U2type GTAG introns. The donors of introns 9 and 10 begin with the dinucleotide GC. Intron 1, like its counterparts in *CACNAIG*, *CACNAIH* (unpublished observations), and *CACNAIA*, is a rare U12type ATAC intron. Exon 1 includes at least 709 bp of 5' untranslated region and the putative start codon.

Fig. 2 shows a schematic of the deduced protein product. Sequence alignment with other members of the α_1 subunit family suggests a transmembrane topology with four domains (D1 – D4), each consisting of six membrane-spanning segments, a pore loop and cytoplasmic and extracellular connecting loops. The domains are linked by interdomain loops (ID12, ID23, ID34), which, along with the amino- (N) and carboxyl- (C) termini, reside in the cytoplasm. Six of the 35 α_1 I splice sites (black bars) are conserved in the other α_1 subunits studied to date, α_{1A} , α_{1C} , α_{1D} , α_{1F} , α_{1S} , α_{1G} and α_{1H} and another three are located within nine nucleotides in the multiple sequence alignment (purple bars). Seventeen of the splice sites (green bars) are in identical locations in the other T subunits, but are not conserved in non-T subunits. Only nine splice sites (pink bars) are unique to α_{1I} ; these sites join exons that contribute to the cytoplasmic ID1-2, ID2-3 and C-terminus. As indicated by residue color-coding, α_{1I} is quite similar to the two other human T α_1 subunits in its membrane-spanning segments — 84% of residues are identical and 92% have similarity scores ≥ 4 (see legend). Likewise, the pore loops and ID34 are similar. Apart from islands of similarity, the large extracellular loop of D1, the N- and C-termini and ID12 and ID23 differ from their counterparts in α_{1G} and α_{1H} . Five potential *N*-glycosylation sites in putative extracellular portions of the protein and 28 potential phosphorylation sites in putative cytoplasmic portions were identified with PROSITE. Although some of the potential phosphorylation sites are conserved among the T α_1 subunits, the majority are unique to α_{1I} . Seventeen extracellular cysteines, including six conserved in all ten reported human α_1 subunits (black and

5 purple hooks) and nine conserved among T α_1 subunits (green hooks), may play a role in maintaining proper conformation of the extracellular portions of the protein.

Regions derived from portions of the RNA subject to alternative processing are highlighted with a blue background. The shortest predicted product
10 (Δ9Δ33AΔ37) has 1,968 aa residues; the longest (Δ36B), 2,223 aa residues. The reported rat orthologue corresponds to the human Δ9Δ36B variant with a few differences. Exon 32 of the human gene lacks an 18-aa stretch of cysteines, glycines and prolines found in rat (arrow). In addition, 40 nt of exon 34 are deleted in the rat sequence. This leads to a frameshift and early termination of the rat aa sequence. In
15 addition, the published rat sequence contains sequencing errors in exon 35.

T currents display heterogeneity of biophysical and pharmacological properties and subcellular localization. Identification of multiple T α_1 subunit genes reveals one likely source of heterogeneity. Indeed, heterologous expression experiments
20 demonstrate biophysical differences among the isoforms. The molecular diversity generated by alternative splicing of T α_1 subunit genes has the potential to yield additional functional diversity. *CACNA1I* is subject to alternative splicing in at least two exons while *CACNA1G* undergoes alternative splicing in at least six (unpublished observations). Variation in channel phosphorylation and isoform-specific interactions with other proteins may also contribute to diversity. Knowledge of the
25 α_{11} aa sequence and its variants will allow explicit tests of these ideas.

EXAMPLE 2

The human chromosome 17 genomic DNA of clone hCIT.22_K_21 (AC004590, Whitehead Institute/MIT Center for Genome Research) appeared to
30 include most or all of *CACNA1G*, a gene encoding the T Ca^{2+} channel α_{1G} subunit. Thirty-four probable exons were identified by *blastn* alignment with the rat α_{1G} cDNA sequence (AF027984). Four potential polyadenylation signals were located by
35 *blastn* alignment with sequences (R40146, R43876, R43935, R46109) derived from the 3' end of infant brain cDNA clones. A provisional cDNA sequence was assembled and primers for polymerase chain reaction (PCR)-amplification of
40 overlapping portions of human brain cDNA (Clontech #74001) were designed with
45 *OLIGO* (National Biosciences).

5 PCR products were fractionated by agarose-gel electrophoresis. When
adequately resolved, individual products were cut from the gel, recovered on a
spin-column (Qiagen #28704), eluted in water and submitted for sequencing. When
10 resolution was incomplete, DNA was recovered from the gel for cloning into
5 pCRΔ2.1-TOPO (Invitrogen #K4500-01). Insert DNA was PCR-amplified from
overnight cultures of white colonies, purified by agarose-gel electrophoresis and
submitted for sequencing. Exon boundaries were determined by comparison of the
15 cDNA and genomic sequences; ambiguity was resolved by matching potential donors
and acceptors to consensus sequences. All reported splice variants were observed in
10 at least two independent PCRs.

20 Fig. 3 shows 25 of the 83 overlapping PCR products (top, black bars) that
contributed to the cDNA sequence (AF134985, AF134986). Also pictured are exon
maps of the cDNA (middle) and the gene (bottom). *CACNA1G* consists of at least
25 38 exons distributed over at least 66,490 basepairs (bp). Thirty-four exons have
15 counterparts in the rat cDNA sequence; exons 14, 26, 34 and 35 are newly-identified.
Most PCRs yielded a single product suggesting constitutive splicing of 32 exons
(colored gray or black in the cDNA and genomic maps). Certain PCRs, however,
yielded multiple products (interrupted black bars), indicative of alternative splicing.
30 PCRs spanning the 69-nucleotide (nt) exon 14 (brown), for example, yielded two
20 products, Δ14 and +14; thus, exon 14 is a cassette exon subject to type A alternative
splicing. PCRs spanning cassette exons 34 (144 nt) and 35 (135 nt) yielded three
35 products (Δ34Δ35, +34Δ35 and +34+35); the Δ34+35 product was not detected.
Sequencing of PCR products spanning exons 25 and 26 revealed that exon 25
harbors an internal donor that leads to type D alternative splicing and deletion of 21
40 25 nt at the 3' end of the exon (defined as exon 25B, red); the 54-nt exon 26 (blue) is a
cassette exon. Exons 25B and 26 appear to be mutually exclusive in that only
Δ25B+26 and +25BΔ26 variants were detected. Sequence data also demonstrated
45 that a 237-nt, protein-coding portion of exon 38 (defined as exon 38B, green) could
be excised as an intron (type E alternative splicing). Additional evidence for
30 alternative processing of the human α_{1G} RNA comes from four clones of a
normalized, oligo(dT)-primed infant brain cDNA library. Sequence derived from
50

these clones (red bars), suggests two polyadenylation sites: an upstream site 321 nt 3' to the stop codon and a downstream site 719 nt 3' to the stop codon. Cleavage at the upstream site would delete 398 nt of the mRNA, defined as exon 38D (purple). Exon 1 includes at least 432 bp of 5' untranslated region and the putative start codon. Introns 2 – 37 are common U2type GTAG introns. Intron 1, like its counterparts in *CACNAIH* (unpublished observations), *CACNAII* (submitted), and *CACNAIA*, is a rare U12type ATAC intron.

Fig. 4 shows a schematic of the deduced protein products encoded by *CACNAIG*. Like other members of the α_1 subunit family, α_{1G} has a proposed transmembrane topology with four domains (D1 – D4), each consisting of six membrane-spanning segments, a pore loop and cytoplasmic and extracellular connecting loops. The domains are linked by interdomain loops (ID12, ID23, ID34), which, along with the amino- (N) and carboxyl- (C) termini, reside in the cytoplasm. Regions derived from portions of the RNA subject to alternative splicing are highlighted with a blue background, with mutually-exclusive exons 25B and 26 placed side-by-side. The shortest predicted product ($\Delta 14+25B\Delta 26\Delta 34\Delta 35\Delta 38B$) has 2,171 amino-acid (aa) residues; the longest ($+14\Delta 25B+26+34+35+38B$), 2,377 aa residues. The reported rat α_{1G} aa sequence corresponds to the human ($14+25B\Delta 26\Delta 34\Delta 35+38B$ splice variant and is 93% identical. Additional features of the α_{1G} protein product including residue similarity to the other T α_1 subunits, comparison of splice sites and sites of potential post-translational modification are shown in Fig. 2 and described in the legend.

Six *CACNAIG* exons undergo alternative splicing, leading to a possible 64 splice variants. Analysis of full-length PCR products is underway to determine relative splice-variant abundance. Of note, all potential variants maintain the open reading frame, leave the transmembrane topology intact and, hence, could be translated into plausible protein products. Individual α_{1G} isoforms may play distinct cellular roles by virtue of differences in biophysical behavior, protein-protein interactions, second-messenger-dependent regulation or other isoform-specific properties.

Claims

5

10

15

20

25

30

35

40

45

50

55

Claims:

1. An isolated and purified α_{1G} subunit of human brain T calcium channel selected from splice variants 1-64 as shown in Table 1.
2. An isolated and purified nucleic acid encoding the α_{1G} subunit of claim 1.
3. The isolated and purified nucleic acid of claim 2 which comprises a human coding sequence as described in Table 1.
4. An isolated and purified polypeptide which comprises a translated exon selected from the group consisting of 1-38D as shown in Table 2.
5. An isolated and purified nucleic acid which comprises an exon selected from the group consisting of 1-38D as shown in Table 2.
6. An isolated and purified α_{1I} subunit of human brain T calcium channel selected from splice variants 1-8 as shown in Table 3.
7. An isolated and purified nucleic acid encoding the α_{1I} subunit of claim 6.
8. The isolated and purified nucleic acid of claim 7 which comprises a human coding sequence as described in Table 3.
9. An isolated and purified polypeptide which comprises a translated exon selected from the group consisting of 1-37 as shown in Table 4.
10. An isolated and purified nucleic acid which comprises an exon selected from the group consisting of 1-37 as shown in Table 4.
11. An expression vector comprising the nucleic acid of claim 2.
12. An expression vector comprising the nucleic acid of claim 3.
13. An expression vector comprising the nucleic acid of claim 7.
14. An expression vector comprising the nucleic acid of claim 8.
15. A host cell comprising an expression vector according to claim 11.
16. A host cell comprising an expression vector according to claim 12.
17. A host cell comprising an expression vector according to claim 13.
18. A host cell comprising an expression vector according to claim 14.
19. A method to identify candidate drugs for treating epilepsy, comprising the steps of:
 - contacting a cell according to claim 15 with a test substance;

5 measuring uptake by the cell of calcium ions, wherein a test substance
which inhibits the uptake by the cell of calcium ions is identified as a candidate drug
for treating epilepsy.

10 20. A method to identify candidate drugs for treating epilepsy, comprising
5 the steps of:

 contacting a cell according to claim 16 with a test substance;
 measuring uptake by the cell of calcium ions, wherein a test substance
15 which inhibits the uptake by the cell of calcium ions is identified as a candidate drug
for treating epilepsy.

10 21. A method to identify candidate drugs for treating epilepsy, comprising
the steps of:

20 contacting a cell according to claim 17 with a test substance;
 measuring uptake by the cell of calcium ions, wherein a test substance
25 which inhibits the uptake by the cell of calcium ions is identified as a candidate drug
for treating epilepsy.

15 22. A method to identify candidate drugs for treating epilepsy, comprising
the steps of:

30 contacting a cell according to claim 18 with a test substance;
 measuring uptake by the cell of calcium ions, wherein a test substance
20 which inhibits the uptake by the cell of calcium ions is identified as a candidate drug
for treating epilepsy.

FIG. 1





FIG. 2








FIG. 3

FIG. 4



5 / 5
FIG. 5

SEQUENCE LISTING

<110> Mittman, Scott
Agnew, William

<120> Human Brain T Calcium Channel Alpha
Subunit Splice Variants

<130> 01107.81105

<160> 164

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 242

<212> DNA

<213> Homo sapiens

<400> 1

atggacgagg aggaggatgg agcggggcgc gaggagtcgg gacagccccg gagcttcattg	60
cggctcaacg acctgtcggg ggccggggggc cggccggggc cggggtcacg agaaaaggac	120
ccgggcagcg cggactccga ggcggagggg ctgccgtacc cggcgctggc cccgggtggtt	180
ttctttctact tgagccagga cagccgcccc cggagctggg gtctccgcac ggtctgtaac	240
cc	242

<210> 2

<211> 112

<212> DNA

<213> Homo sapiens

<400> 2

ctggtttgag cgcacagca tggttgatc cttctcaac tgcgtgaccc tgggcatgtt	60
cgggccatgc gaggacatcg cctgtgactc ccagcgtgc cggatcctgc ag	112

<210> 3

<211> 134

<212> DNA

<213> Homo sapiens

<400> 3

gcctttgatg acttcattt tgccttctt gccgtggaga tgggtgtgaa gatggtggcc	60
ttgggcatct ttgggaaaaa gtgttacctg ggagacactt ggaaccggct tgactttttc	120
atcgtcatcg cagg	134

<210> 4

<211> 98

<212> DNA

<213> Homo sapiens

<400> 4

gatgctggag tactcgtgg acctgcagaa cgtcagcttc tcagctgtca ggacagtccg	60
tgtgctgca cgcgtcagg ccattaaccg ggtgccca	98

<210> 5
 <211> 160
 <212> DNA
 <213> Homo sapiens

<400> 5
 gcacgcgcacat ccttgctcagc ttgctgctgg atacgctgcc catgctgggc aacgtcctgc 60
 tgctctgctt cttcgtcttc ttcatcttcg gcacgctcgg cgtccagctg tgggcagggc 120
 tgcttcggaa cagatgcttc ctacctgaga atttcagcct 160

<210> 6
 <211> 301
 <212> DNA
 <213> Homo sapiens

<400> 6
 ccccttgagc gtggacctgg agcgtatatta ccagacagag aacgaggatg agagcccctt 60
 catctgctcc cagccacgcg agaacggcat gcggtcctgc agaagcgtgc ccacgctgcg 120
 cggggacggg ggcgggtggc caccctgcgg tctggactat gaggcctaca acagctccag 180
 caacaccacc tgtgtcaact ggaaccagta ctacaccaac tgctcagcgg gggagcacia 240
 ccccttcaag ggcgccatca actttgacaa catttgctat gcctggatcg ccatcttcca 300
 g 301

<210> 7
 <211> 93
 <212> DNA
 <213> Homo sapiens

<400> 7
 gtcacacgc tggagggtcg ggtcgacatc atgtactttg tgatggatgc tcattccttc 60
 tacaatttca tctacttcat cctcctcacc atc 93

<210> 8
 <211> 784
 <212> DNA
 <213> Homo sapiens

<400> 8
 gtgggctcct tcttcatgat caacctgtgc ctgggtggta ttgccacgca gttctcagag 60
 accaagcagc gggaaagcca gctgatgcgg gagcagcgtg tgcggttcct gtccaaagcc 120
 agcacctcgg ctatgctctc tgagcccgcc agctgctatg aggagctgct caagtacctg 180
 gtgtacatcc ttctgaaggc agcccgccag ctggctcagg tctctcgggc agcagggtgtg 240
 cgggttgggc tgctcagcag cccagcacc ctcggggggc aggagaccca gccacgcagc 300
 agctgctctc gctccaccg ccgcctatcc gtccaccacc tgggtgcacca ccaccaccac 360
 catcaccacc actaccacct gggcaatggg acgctcaggg ccccccgggc cagcccgag 420
 atccaggaca gggatgccaa tgggtcccg aggtcctatg tgccaccacc ctcgacgcct 480
 gccctctccg gggccccccc tgggtggcga gactctgtgc acagcttcta ccatgcccag 540
 tgccacttag agccagtcgg ctgcccaggc cccctcccca ggtcccatc tgaggcatcc 600
 ggcaggactg tgggcagcgg gaaggtgtat cccaccgtgc acaccagccc tccaccggag 660
 acgctgaagg agaaggcact agtagagggt gctgccagct ctgggcccc aacctcacc 720
 agcctcaaca tcccaccgg gccctacagc tccatgcaca agctgctgga gacacagagt 780
 acag 784

<210> 9
 <211> 377

<212> DNA
<213> Homo sapiens

<400> 9
gtgcctgcc aagctcttgc aagatctcca gcccttgctt gaaagcagac agtggagcct 60
gtggtccaga cagctgcccc tactgtgccc gggccggggc aggggaggtg gagctcggcg 120
accgtgaaat gcttgactca gacagcgagg cagtttatga gttcacacag gatgcccgagc 180
acagcgacct ccgggacccc cacagccggc ggcaacggag cctggggccca gatgcagagc 240
ccagctctgt gctggccttc tggaggctaa tctgtgacac ctccgaaaag attgtggaca 300
gcaagtactt tggccgggga atcatgatcg ccactctggt caacacactc agcatgggca 360
tcgaatacca cgagcag 377

<210> 10
<211> 152
<212> DNA
<213> Homo sapiens

<400> 10
cccaggagc ttaccaacgc cctagaaatc agcaacatcg tcttcaccag cctctttgcc 60
ctggagatgc tgctgaagct gcttgtgtat ggtccctttg gctacatcaa gaatccctac 120
aacatcttcg atgggtgcat tgtggtoate ag 152

<210> 11
<211> 186
<212> DNA
<213> Homo sapiens

<400> 11
cgtgtgggag atcgtggggc agcagggggg cggcctgtcg gtgctgcgga ccttcgcct 60
gatgcgtgtg ctgaagctgg tgcgcttctt gccggcgctg cagcggcagc tgggtggtgt 120
catgaagacc atggacaacg tggccacctt ctgcatgctg cttatgtctt tcatcttcat 180
cttcag 186

<210> 12
<211> 115
<212> DNA
<213> Homo sapiens

<400> 12
cactctgggc atgcattctt tcggctgcaa gtttgctctt gagegggatg gggacaccct 60
gccagaccgg aagaattttg actccttgct ctggggccatc gtcactgtct ttcag 115

<210> 13
<211> 156
<212> DNA
<213> Homo sapiens

<400> 13
atcctgaccc aggaggactg gaacaaagtc ctctacaatg gtatggcctc cactgcgtcc 60
tggggggccc tttatttcat tgccctcatg accttcggca actacgtgct cttcaatttg 120
ctggctgccca ttctggtgga gggcttcag gaggag 156

<210> 14
<211> 69
<212> DNA

<213> Homo sapiens

<400> 14

gaaatcagca aacgggaaga tgcgagtga cagttaagct gtattcagct gcctgtcgac 60
tcccagggg 69

<210> 15

<211> 85

<212> DNA

<213> Homo sapiens

<400> 15

ggagatgcca acaagtccga atcagagccc gattttcttct caccagcct ggatggtgat 60
ggggacagga agaagtgctt ggct 85

<210> 16

<211> 194

<212> DNA

<213> Homo sapiens

<400> 16

tggtgtccct gggagagcac cgggagctgc ggaagagcct getgcgcct ctcatcatcc 60
acacggccgc cacacccatg tcgctgcccc agagcaccag caccggcctg ggcgagggcg 120
tgggcccctgc gtcgcgcgc accagcagca gcgggtcggc agagcctggg gcggcccacg 180
agatgaagtc accg 194

<210> 17

<211> 432

<212> DNA

<213> Homo sapiens

<400> 17

cccagcgccc gcagctctcc gcacagcccc tggagcgtg caagcagctg gaccagcagg 60
cgctccagcc ggaacagcct cggcgtgca cccagcctga agcggagaag cccaagtggg 120
gagcggcggc ccctgttgtc gggagaaggc caggagagcc aggatgaaga ggagagctca 180
gaagaggagc gggccagccc tgcgggcagt gaccatcgcc acagggggtc cctggagcgg 240
gaggccaaga gtccctttga cctgccagac aactgcagg tgccagggtc gcatcgact 300
gccagtggcc gagggctctc ttctgagcac caggactgca atggcaagtc ggcttcaggg 360
cgccctggccc gggccttcgc gcctgatgac cccccactgg atggggatga cgccgatgac 420
gagggaacc tg 432

<210> 18

<211> 101

<212> DNA

<213> Homo sapiens

<400> 18

agcaaagggg aacgggtccg cgcgtggatc cgagcccagc tccctgcctg ctgcctcgag 60
cgagactcct ggtcagccta catcttcct cctcagcca g 101

<210> 19

<211> 124

<212> DNA

<213> Homo sapiens

<400> 19
 gttcgcctc ctgtgtcacc ggatcatcac ccacaagatg ttcgaccacg tggtccttgt 60
 catcatcttc cttaactgca tcaccatcgc catggagcgc cccaaaattg acccccacag 120
 cgct 124

<210> 20
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 20
 gaacgcattct tcttgaccct ctccaattac atcttcaccg cagtctttct ggctgaaatg 60
 acagtgaag 69

<210> 21
 <211> 185
 <212> DNA
 <213> Homo sapiens

<400> 21
 gtggtggcac tgggctgggtg ctctggggag caggcgtacc tgggagcag ttggaacgtg 60
 ctggacgggc tgggtgtgct catctccgtc atcgacatc tgggtgcat ggtctctgac 120
 agcggcacca agatcctggg catgctgagg gtgctgaggc tgetgaggac cctgcgccg 180
 ctgag 185

<210> 22
 <211> 127
 <212> DNA
 <213> Homo sapiens

<400> 22
 ggtgatcagc cgggcgcagg ggctgaagct ggtgggtggag acgctgatgt cctcactgaa 60
 acccatcggc aacattgtag tcattctgtg tgccttcttc atcattttcg gcattctggg 120
 ggtgcag 127

<210> 23
 <211> 126
 <212> DNA
 <213> Homo sapiens

<400> 23
 ctcttcaaag ggaagttttt cgtgtgccag ggcgaggata ccaggaacat caccaataaa 60
 teggaactgtg ccgaggccag ttaccgggtg gtcgggcaca agtacaactt tgacaacctt 120
 ggccag 126

<210> 24
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 24
 gccctgatgt ccctgttcgt ttggcctcc aaggatggtt ggggtggacat catgtacgat 60
 gggctggatg ctgtgggcgt ggaccagcag 90

<210> 25

<211> 193
 <212> DNA
 <213> Homo sapiens

<400> 25
 cccatcatga accacaaccc ctggatgctg ctgtacttca tctcgttcct gctcattgtg 60
 gccttctttg tctgaacat gtttgtgggt gtggtgggtg agaacttcca caagtgtcgg 120
 cagcaccagg aggaagagga ggcccggcgg cgggaggaga agcgcctacy aagactggag 180
 aaaaagagaa gga 193

<210> 26
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 26
 gtaaggagaa gcagatggct g 21

<210> 27
 <211> 54
 <212> DNA
 <213> Homo sapiens

<400> 27
 atctaattgt ggacgatgta attgcttccg gcagctcagc cagcgtgctg tcag 54

<210> 28
 <211> 152
 <212> DNA
 <213> Homo sapiens

<400> 28
 aagcccagtg caaaccttac tactccgact actcccgtt cggctcctc gtccaccact 60
 tgtgcaccag ccactacctg gacctcttca tcacagggtg catcgggctg aacgtggtca 120
 ccatggccat ggagcactac cagcagcccc ag 152

<210> 29
 <211> 110
 <212> DNA
 <213> Homo sapiens

<400> 29
 attctggatg aggcctctgaa gatctgcaac tacatcttca ctgtcatctt tgtcttggag 60
 tcagttttca aacttgtggc ctttggtttc cgtcgggtct tccaggacag 110

<210> 30
 <211> 134
 <212> DNA
 <213> Homo sapiens

<400> 30
 gtggaaccag ctggacctgg ccattgtgct gctgtccatc atgggcatca cgctggagga 60
 aatcgaggtc aacgcctgc tgcccatcaa cccaccatc atccgcatca tgaggggtgct 120
 gcgcattgcc cgag 134

<210> 31
 <211> 71
 <212> DNA
 <213> Homo sapiens

<400> 31
 tgctgaagct gctgaagatg gctgtgggca tgcggggcgt gctggacacg gtgatgcagg 60
 ccctgcccc g 71

<210> 32
 <211> 79
 <212> DNA
 <213> Homo sapiens

<400> 32
 gtggggaacc tgggacttct cttcatgttg ttgttttca tctttgcagc tetgggcgtg 60
 gagctctttg gagacctgg 79

<210> 33
 <211> 122
 <212> DNA
 <213> Homo sapiens

<400> 33
 agtgtgacga gacacacccc tgtgagggcc tgggcccgtca tggcaccttt cggaactttg 60
 gcatggcctt cctaaccctc ttccgagtct ccacaggaga caattggaat ggcattatga 120
 ag 122

<210> 34
 <211> 354
 <212> DNA
 <213> Homo sapiens

<400> 34
 gacacccctcc gggactgtga ccaggagtcc acctgctaca acacggatcat ctgcctatc 60
 tactttgtgt ccttctgtgt gacggcccag ttctgtctag tcaacgtggg gatcgccgtg 120
 ctgatgaagc acctggagga gagcaacaag gaggccaagg agggggccga gctagaggct 180
 gagctggagc tggagatgaa gaccctcagc cccagccccc actcgccact gggcagcccc 240
 ttctctggc ctggggctga gggcccccag agcccccaga gcccgaagcc tggggctctg 300
 caccagcggg cccacgcgag atcagcctcc cacttttccc tggagcacc cacc 354

<210> 35
 <211> 144
 <212> DNA
 <213> Homo sapiens

<400> 35
 gacaggcagc tgtttgacac catatccctg ctgatccagg gctccctgga gtgggagctg 60
 aagctgatgg acgagctggc agggccaggg ggccagccct ctgccttccc ttctgcccc 120
 agcctgggag gctccgaccc acag 144

<210> 36
 <211> 135
 <212> DNA
 <213> Homo sapiens

<400> 36
 atccctctag ctgagatgga ggctctgtct ctgacgtcag agattgtgtc tgaaccgtcc 60
 tgcctctctag ctctgaaggga tgactctttg cctgatgaca tgcacacact cttacttagt 120
 gccctggaga gcaat 135

<210> 37
 <211> 169
 <212> DNA
 <213> Homo sapiens

<400> 37
 atgcagcccc accccacgga gctgccagga ccagacttac tgactgtgcg gaagtctggg 60
 gtcagccgaa cgcactctct gcccaatgac agctacatgt gtcggcatgg gagcactgcc 120
 gaggggcccc tgggacacag gggctggggg ctccccaag ctcaagtcag 169

<210> 38
 <211> 170
 <212> DNA
 <213> Homo sapiens

<400> 38
 gctcgtctt gtcggttcac tccagccag cagataccag ctacatcctg cagcttccca 60
 aagatgcacc tcactgtctc cagcccccaca ggcgcccaac ctggggcacc atccccaac 120
 tgcccccacc aggagctcc cctttgctc agaggccact caggcgccag 170

<210> 39
 <211> 66
 <212> DNA
 <213> Homo sapiens

<400> 39
 gcagcaataa ggactgactc cttggacgtt cagggctctgg gcagccggga agacctgtg 60
 gcagag 66

<210> 40
 <211> 237
 <212> DNA
 <213> Homo sapiens

<400> 40
 gtgagtgggc cctccccgcc cctggcccg gcctactctt tctggggcca gtcaagtacc 60
 caggcacagc agcactcccg cagccacagc aagatctcca agcactgac cccgccagcc 120
 ccttgccag gcccagaacc caactggggc aagggccctc cagagaccag aagcagctta 180
 gagttggaca cggagctgag ctggatttca ggagacctcc tgccccctgg cggccag 237

<210> 41
 <211> 753
 <212> DNA
 <213> Homo sapiens

<400> 41
 gaggagcccc catccccag ggacctgaag aagtgtctaca gcgtggaggc ccagagctgc 60
 cagcgccggc ctactgtctg gctggatgag cagaggagac actctatgc cgtcagctgc 120
 ctggacagcg gctcccaacc ccacctgggc acagacccct ctaaccttgg gggccagcct 180
 cttggggggc ctgggagccg gcccaagaaa aaactcagcc cgcctagtat caccatagac 240

```

ccccccgaga gccaaaggtcc tgggaccccg cccagccctg gtatctgcct ccggaggagg 300
gctccgtcca gcgactccaa ggatcccttg gcctctggcc cccctgacag catggctgcc 360
tcgcccctccc caaagaaaga tgtgtgtagt ctctccggtt tatcctctga cccagcagac 420
ctggacccct gagtcctgcc ccactttccc actcaccttt ctccactggg tgccaagtcc 480
tagctcctcc tectgggcta tattcctgac aaaagttcca tatagacacc aaggaggcgg 540
aggcgtcct cctgcctca gtggctctgg gtacctgcaa gcagaacttc caaagagagt 600
taaaagcagc agccccggca actctggctc caggcagaag gagaggcccg gtgcagctga 660
ggttcccagc accagaagct gttgggagaa agcaatacgt ttgtgcagaa tctctatgta 720
tattctattt tattaaatta attgaatcta gta 753

```

<210> 42
 <211> 402
 <212> DNA
 <213> Homo sapiens

```

<400> 42
tatgctgggat gtacgacatt ttgtgactga agagacttgt ttccttctac ttttatgtgt 60
ctcagaatat ttttgaggcg aaggcgtctg tctcttggct attttaacct aaaataacag 120
tctagtata ttcctcttc ttgcaagca caagctggga ccgcgagcac attgcagccc 180
caacggtggc ccatcttcag cggagagcga gaaccatttt ggaaactgta atgtaactta 240
tttttctct taacctcgtc atcattttct gtagggaaaa aaaaaagaaa aagaaaaaat 300
gagattttac aagtgaatg gaaccttttt atatacatat acatacatat ctatctatct 360
atctatatat atataaaata aagtaatttt cctaaataaa aa 402

```

<210> 43
 <211> 236
 <212> DNA
 <213> Homo sapiens

```

<400> 43
atggctgaga gcgcctcccc gccctcctca tctgcagcag cccagccgc tgagccagga 60
gtcaccacgg agcagcccg accccggagc ccccatcct ccccgccagg cctggaggag 120
cctctggatg gagctgatcc tcatgtacca caccagacc tggcgctat tgccttcttc 180
tgctgcgac agaccaccag ccccggaac tgggtcatca agatggtgtg caaccc 236

```

<210> 44
 <211> 112
 <212> DNA
 <213> Homo sapiens

```

<400> 44
gtggtttgaa tgtgtcagca tgetggtgat cctgctgaac tgcgtgacac ttggcatgta 60
ccagccgtgc gacgacatgg actgcctgtc cgaccgtgc aagatcctgc ag 112

```

<210> 45
 <211> 134
 <212> DNA
 <213> Homo sapiens

```

<400> 45
gtctttgatg acttcattct tatctcttt gccatggaga tgggtctcaa gatggtggcc 60
ctggggattt ttggcaagaa gtgtacctc ggggacacat ggaaccgcct ggatttcttc 120
atcgtcatgg cagg 134

```

<210> 46

<211> 98
 <212> DNA
 <213> Homo sapiens

<400> 46
 gatgggtcgag tactccctgg accttcagaa catcaacctg tcagccatcc gcaccgtgag 60
 cgtcctgagg cccctcaaag ccatcaaccg cgtgccca 98

<210> 47
 <211> 160
 <212> DNA
 <213> Homo sapiens

<400> 47
 gtatgaggat cctggtgaac ctgctcctgg acacactgcc catgctgggg aatgtcctgc 60
 tgctctgctt ctttgtcttc ttcatctttg gcatcatagg tgtgcagctc tgggcggggc 120
 tgctcgtaa ccgtgcttc ctggaggaga acttcacat 160

<210> 48
 <211> 316
 <212> DNA
 <213> Homo sapiens

<400> 48
 acaaggggat gtggccttgc cccatacta ccagccggag gaggatgatg agatgcctt 60
 catctgctcc ctgtcgggag acaatgggat aatgggctgc catgagatcc ccccgctcaa 120
 ggagcagggc cgtgagtgtc gcctgtccaa ggacgacgtc tacgactttg gggcggggcg 180
 ccaggacctc aatgccagcg gcctctgtgt caactgggaa cgttactaca atgtgtgccc 240
 cacgggcagc gccaaccccc acaaggggtgc catcaacttt gacaacatcg gttatgcttg 300
 gattgtcatt ttccag 316

<210> 49
 <211> 93
 <212> DNA
 <213> Homo sapiens

<400> 49
 gtgatcacte tggaggctg ggtggagatc atgtactacy tgatggatgc tcaactcttc 60
 tacaacttca tetacttcat cctgcttacc ata 93

<210> 50
 <211> 313
 <212> DNA
 <213> Homo sapiens

<400> 50
 gtgggctcct tcttcatgat caacctgtgc ctggtgtca tagcgacca gttctcggag 60
 accaagcaac gggagcaccg gctgatgctg gacgagcggc agcgctacct gtcctccagc 120
 acgggtggca gctacgcga gcctggcgac tgctacgagg agatcttcca gtatgtctgc 180
 cacatcctgc gcaaggccaa gcgcgcggcc ctgggcctct accaggccct gcagagccgg 240
 cggcaggccc tgggcccga ggccccggcc ccggccaaac ctgggcccga cgccaaggag 300
 ccccggcact acc 313

<210> 51
 <211> 105

<212> DNA

<213> Homo sapiens

<400> 51

atgggaagac taaggggtcag ggagatgaag ggagacatct cggaagccgg cattgccaga	60
ctttgcatgg gctgcctcc cctggaaatg atcactcggg aagag	105

<210> 52

<211> 425

<212> DNA

<213> Homo sapiens

<400> 52

agctgtgccc gcaacatagc cccctggatg cgacgcccga caccctgggtg cagcccatcc	60
ccgccacgct ggcttccgat cccgccagct gcccttgctg ccagcatgag gacggccggc	120
ggccctcggg cctgggcagc accgactcgg gccaggaggg ctcgggctcc gggagctccg	180
ctggtggcga ggacgaggcg gatggggacg gggcccgag cagcgaggac ggagcctcct	240
cagaactggg gaaggaggag gaggaggagg agcaggcggg tggggcggtc tggctgtgag	300
gggatgtgtg ggggagacg cgagccaagc tgcgcggcat cgtggacagc aagtacttca	360
accggggcat catgatggcc atcctgtgta acaccgtcag catgggcatc gagcaccacg	420
agcag	425

<210> 53

<211> 152

<212> DNA

<213> Homo sapiens

<400> 53

ccggaggagc tgaccaacat cctggagatc tgcaatgtgg tcttcaccag catgtttgcc	60
ctggagatga tcctgaagct ggctgcattt gggctcttcg actacctgag taaccctac	120
aacatcttcg acagcatcat tgtcatcac ag	152

<210> 54

<211> 186

<212> DNA

<213> Homo sapiens

<400> 54

catctgggag atcgtggggc agggggacgg tgggtgtgag gtgctgcgga ccttcgggct	60
gctgcgcgtg ctgaaactgg tgcgcttcat gcccgccctg cggcgccagc tcgtgggtgct	120
catgaagacc atggacaacg tggccacctt ctgcatgctg ctcatgctct tcactttcat	180
cttcag	186

<210> 55

<211> 118

<212> DNA

<213> Homo sapiens

<400> 55

catccttggg atgcatattt ttgctgcaa gttcagcctc cgcacggaca ctggagacac	60
ggtgcccagc aggaagaact tcgactcctt gctgtgggac atcgtcactg tgttcacg	118

<210> 56

<211> 156

<212> DNA

<213> Homo sapiens

<400> 56

atcctcacc	aggaggactg	gaacgtcgtt	ctctacaatg	gcattggctc	cattctccc	60
tgggcctccc	tctactttgt	cgccctcatg	accttcggca	actatgtgct	cttcaacctg	120
ctggtggcca	tcctggtgga	gggcttcag	gcggag			156

<210> 57

<211> 94

<212> DNA

<213> Homo sapiens

<400> 57

ggtgacgcca	atcgctccta	ctcggacgag	gaccagagct	catccaacat	agaagagttt	60
gataagctcc	aggaaggcct	ggacagcagc	ggag			94

<210> 58

<211> 203

<212> DNA

<213> Homo sapiens

<400> 58

atcccaagct	ctgccaatc	cccatgacc	ccaatgggca	cctggacccc	agtctcccac	60
tgggtgggca	cctaggtcct	gctggggctg	cgggacctgc	cccccgactc	tcactgcagc	120
cggaacccat	gctggtggcc	ctgggctccc	gaaagagcag	tgatcatgtc	ctaggagagga	180
tgagctatga	ccagcgctcc	ctg				203

<210> 59

<211> 471

<212> DNA

<213> Homo sapiens

<400> 59

tccagctccc	ggagctccta	ctacgggcca	tggggccgca	gcgcggcctg	ggccagccgt	60
cgctccagct	ggaacagcct	caagcacaa	ccgcccgtcg	cgagcatga	gtccctgctc	120
tctgaggagc	gcggcgggcg	cgcccggtc	tgcgaggttg	ccgcggacga	ggggccgcgc	180
cgggccgcac	ccctgcacac	cccacacgcc	caccacattc	atcacgggcc	ccatctggcg	240
caccgccacc	gccaccaccg	ccggacgctg	tccctcgaca	acaggggactc	ggtggacctg	300
gccgagctgg	tgcccgcggt	gggcgcccac	ccccgggccc	cctggagggc	ggcaggcccc	360
gcccccgggc	atgaggactg	caatggcagg	atgcccagca	tcgccaaaga	cgtcttcacc	420
aagatggggc	accgcgggga	tcgcggggag	gatgaggagg	aatcgacta	c	471

<210> 60

<211> 101

<212> DNA

<213> Homo sapiens

<400> 60

acctgtgtgt	tccgcgtccg	caagatgac	gacgtctata	agcccgactg	gtgcgaggtc	60
cggaagact	ggtctgtcta	cctcttctct	cccgagaaca	g		101

<210> 61

<211> 124

<212> DNA

<213> Homo sapiens

<400> 61
 gtccgggtc ctgtgtcaga ccattattgc ccacaaactc ttgactacg tegtctggc 60
 cttcatcttt ctcaactgca tcaccatgc cctggagcgg cctcagatcg aggcggcag 120
 cacc 124

<210> 62
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 62
 gaacgcattc ttctcacctg gtccaactac atcttcacgg ccatcttcgt gggcgagatg 60
 acattgaag 69

<210> 63
 <211> 185
 <212> DNA
 <213> Homo sapiens

<400> 63
 gtagtctcgc tgggcctgta ctccggcgag caggcgtacc tacgcagcag ctggaacgtg 60
 ctggatggtc ttcttgtctt cgtgtccatc atcgacatcg tgggtgccct ggcctcagcc 120
 gggggagcca agatcttggg ggtcctccga gtcttgccgc tctgcgcac cctacgccc 180
 ctgcg 185

<210> 64
 <211> 127
 <212> DNA
 <213> Homo sapiens

<400> 64
 tgtcatcagc cgggcgcggc gctgaagct ggtggtggag acaactcatc cctccctcaa 60
 gcccatcggc aacatcgtgc tcactgtgtg tgccttcttc atcatctttg gcacccctggg 120
 agtcag 127

<210> 65
 <211> 126
 <212> DNA
 <213> Homo sapiens

<400> 65
 ctcttcaagg gcaagttcta ccaactgtctg gggtgggaca cccgcaacat caccaaccgc 60
 tcggactgca tggccgcaa ctaccgttg gtccatcaca aatacaactt cgacaacctg 120
 ggccag 126

<210> 66
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 66
 gctctgatgt cctctttgt cctggcatcc aaggatggtt gggatgaacat catgtacaat 60
 ggactggatg ctgttgctgt ggaccagcag 90

<210> 67

<211> 193
 <212> DNA
 <213> Homo sapiens

<400> 67
 cctgtgacca accacaaccc ctggatgctg ctgtacttca tctccttctt gctcatcgtc 60
 agcttctttg tgctcaacat gtttgtgggt gtcgtggtgg agaacttcca caagtgcggg 120
 cagcaccagg aggctgaaga ggcacggcgg cgtgaggaga agcggctgcg gcgcctggag 180
 aagaagcgcc gga 193

<210> 68
 <211> 152
 <212> DNA
 <213> Homo sapiens

<400> 68
 agggccagcg gctgcectac tatgccacct attgtcacac ccggtgctc atccactcca 60
 tgtgcaccag ccactacctg gacatcttca tcaccttcac catctgcctc aacgtggtca 120
 ccatgtccct ggagcactac aatcagccca cg 152

<210> 69
 <211> 110
 <212> DNA
 <213> Homo sapiens

<400> 69
 tccctggaga cagccctcaa gtactgcaac tatatgttca ccactgtctt tgtgctggag 60
 gctgtgtctg agctggtggc atttggctcg aggcgcttct tcaaggaccg 110

<210> 70
 <211> 134
 <212> DNA
 <213> Homo sapiens

<400> 70
 atggaaccag ctggacctgg ccattgtgct actgtcagtc atgggcatca ccctggagga 60
 gatcgagatc aatgcggccc tgcccatcaa tcccaccatc atccgcatca tgagggttct 120
 gcgcattgcc cgag 134

<210> 71
 <211> 71
 <212> DNA
 <213> Homo sapiens

<400> 71
 tgctgaagct gttgaagatg gccacaggaa tgccggccct gctggacacg gtggtgcaag 60
 ctttgcccca g 71

<210> 72
 <211> 79
 <212> DNA
 <213> Homo sapiens

<400> 72
 gtgggcaacc tgggcctcct cttcatgctg ctcttcttca tctatgctgc tctcggggtg 60

gagctctttg ggaagctgg

79

<210> 73
 <211> 122
 <212> DNA
 <213> Homo sapiens

<400> 73

tctgcaacga cgagaacccg tgcgagggca tgagccggca tgccaccttc gagaacttcg 60
 gcatggcctt cctcacactc ttccaggctt ccacgggtga caactggaac gggatcatga 120
 ag 122

<210> 74
 <211> 339
 <212> DNA
 <213> Homo sapiens

<400> 74

gacacgctgc gggactgcac ccacgacgag cgcagctgcc tgagcagcct gcagtttgtg 60
 tcgccgctgt acttcgtgag cttcgtgctc acccgcgagt tcgtgctcat caacgtggtg 120
 gtggctgtgc tcataagca cctggacgac agcaacaagg aggcgcagga ggacgcogag 180
 atggatgccg agctcgagct ggagatggcc catggcctgg gccctggccc gaggtgcct 240
 accggctccc cggggcggcc tggccgaggg ccgggagggg cgggcggcgg gggcgacacc 300
 gagggcggct tgtgccggcg ctgctactcg cctgcccgag 339

<210> 75
 <211> 39
 <212> DNA
 <213> Homo sapiens

<400> 75

gagaacctgt ggctggacag cgtctcttta atcatcaag 39

<210> 76
 <211> 108
 <212> DNA
 <213> Homo sapiens

<400> 76

gactccttgg agggggagct gaccatcacc gacaacctgt cgggctccat ctccaccac 60
 tactcctgcg ctgccggctg caagaagtgt caccacgaca agcaagag 108

<210> 77
 <211> 123
 <212> DNA
 <213> Homo sapiens

<400> 77

gtgcagctgg ctgagacgga ggccttctcc ctgaactcag acaggctcct gtccatcctg 60
 ctgggtgacg acctgagtct cgaggacccc acagcctgcc cacctggccg caaagacagc 120
 aag 123

<210> 78
 <211> 166
 <212> DNA

<213> Homo sapiens

<400> 78

ggtgagctgg	acccacctga	gcccattgct	gtgggagacc	tgggcgaatg	cttcttcccc	60
ttgtcctcta	cgcccgctct	gccggatcca	gagaacttcc	tgtgtgagat	ggaggagatc	120
ccattcaacc	ctgtccggtc	ctggctgaaa	catgacagca	gtcaag		166

<210> 79

<211> 197

<212> DNA

<213> Homo sapiens

<400> 79

cacccccaa	gtcccttctc	ccggatgcct	ccagccctct	cctgcccattg	ccagccgagt	60
tcttccaccc	tgcagtgtct	gccagccaga	aaggcccgag	aaaggccact	ggcactggaa	120
ccctcccaaa	gattgcgctg	cagggtcctc	gggcatctct	gcggtcacca	agggtcaact	180
gtaccctcct	ccggcag					197

<210> 80

<211> 713

<212> DNA

<213> Homo sapiens

<400> 80

gtaccgacac	ctcccaggcc	ctagagcact	ggtctgtggg	caaggggcag	gatctaagcc	60
agggcctgaa	gtccaaggga	ctgggagggg	aaggacccaa	ccaaaggccg	agggcaccac	120
cgtgcaaggg	ggtttgggaa	cgctgggggtg	acgctgagac	tggaggggga	ggtggcactg	180
gggcggatgg	agtgggcggg	gctgggtcct	ggggacagca	gagtgtgggg	aggaccccaa	240
ggcgggtctg	gaagaggcct	gtgatcccta	gcttgagggg	aggggaggag	aggaggagga	300
gtactggagg	ttttgcaggg	tggcgggggtg	ctggcagtgg	ggaggacacc	ctgggtgctc	360
tgggtgggtg	tgagtggggg	cttgattact	aggaatggag	gtgggagggc	gggtctgggtg	420
gatgagaagc	ctcgggctgc	agggtccccc	gtactggatt	ggccagggcc	acagccctcc	480
taccacaggg	cacacagagg	tctgaagcac	tgagggtctc	gctgtggggg	tggggaaatg	540
gggcggggcc	ggctcccaca	gtgagtgcag	ttgattcact	gggtgaactg	ctgacccctc	600
acaccaggct	gtgtgctctg	gcgggcaggga	cacaaactcc	ctgcctgcgc	ggctcactgt	660
ttagtgctga	gagtgcgctg	cctgggtgca	ggagggatga	taaccaaaat	aaa	713

<210> 81

<211> 963

<212> DNA

<213> Homo sapiens

<400> 81

gccaccggga	gcgacacgtc	gctggacgcc	agccccagca	gctccggggg	cagcctgcag	60
accacgctcg	aggacagcct	gacctgagc	gacagccccc	ggcgtgccct	ggggccgccc	120
gcgcctgctc	caggaccccg	ggcgggctg	tccccgcgcg	ctcgcgcgcg	cctgagcctg	180
cgcgccgggg	gcctcttcag	cctgcggggg	ctgcggggcg	atcagcgagc	ccacagcagc	240
gggggctcca	ccagcccggg	ctgcacccac	cacgactcca	tggacccctc	ggacgaggag	300
ggccggcggtg	gcgcggggcg	cgggggcgcg	ggcagcgagc	actcggagac	cctcagcagc	360
ctctcgetca	cctccctctt	ctgcccgcgc	ccccgcgcgc	cagcccccg	cctcagcggc	420
gccaggaagt	tcagcagcac	cagcagcctg	gccgcccccg	gccgccccca	cgccgcgcgc	480
ctggcccacg	gcctggcccg	gagccctctg	tgggcccgcg	accgcagcaa	ggaccccccc	540
ggccggggcag	cgctgcccct	gggctggggc	cccttggcg	ccccgcgcga	accgctcccc	600
ggagagctgg	agccgggaga	cgccgccagc	aagagggaag	gatgagggtc	gcaggggccc	660
ccggccgccc	accgcccgc	ccgtctcacc	ttctttacct	caggagccag	gagcagacag	720

```

caataacttcg tccacacctg ggatcgcgca gggcccgag ggcacaggcg cccgacagcc 780
gggctgagcg gagtctgggt tagccaggcc tgcgtggccc atggtggccc ttccagtgea 840
tatacatata tatatatata tatatgcata tatatatata tatatatata tatgtgtata 900
cacacacaca tagacagaca tatatatata tatttatttt ttttactgag agcttatgac 960
ttc 963

```

<210> 82
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 82

```

Met Asp Glu Glu Asp Gly Ala Gly Ala Glu Glu Ser Gly Gln Pro
 1          5          10          15
Arg Ser Phe Met Arg Leu Asn Asp Leu Ser Gly Ala Gly Gly Arg Pro
          20          25          30
Gly Pro Gly Ser Ala Glu Lys Asp Pro Gly Ser Ala Asp Ser Glu Ala
          35          40          45
Glu Gly Leu Pro Tyr Pro Ala Leu Ala Pro Val Val Phe Phe Tyr Leu
          50          55          60
Ser Gln Asp Ser Arg Pro Arg Ser Trp Cys Leu Arg Thr Val Cys Asn
65          70          75          80
Pro

```

<210> 83
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 83

```

Trp Phe Glu Arg Ile Ser Met Leu Val Ile Leu Leu Asn Cys Val Thr
 1          5          10          15
Leu Gly Met Phe Arg Pro Cys Glu Asp Ile Ala Cys Asp Ser Gln Arg
          20          25          30
Cys Arg Ile Leu Gln
          35

```

<210> 84
 <211> 45
 <212> PRT
 <213> Homo sapiens

<400> 84

```

Ala Phe Asp Asp Phe Ile Phe Ala Phe Phe Ala Val Glu Met Val Val
 1          5          10          15
Lys Met Val Ala Leu Gly Ile Phe Gly Lys Lys Cys Tyr Leu Gly Asp
          20          25          30
Thr Trp Asn Arg Leu Asp Phe Phe Ile Val Ile Ala Gly
          35          40          45

```

<210> 85
 <211> 32
 <212> PRT
 <213> Homo sapiens

<400> 85

Met Leu Glu Tyr Ser Leu Asp Leu Gln Asn Val Ser Phe Ser Ala Val
 1 5 10 15
 Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala Ile Asn Arg Val Pro
 20 25 30

<210> 86

<211> 54

<212> PRT

<213> Homo sapiens

<400> 86

Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp Thr Leu Pro Met Leu
 1 5 10 15
 Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe Phe Ile Phe Gly Ile
 20 25 30
 Val Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu
 35 40 45
 Pro Glu Asn Phe Ser Leu
 50

<210> 87

<211> 100

<212> PRT

<213> Homo sapiens

<400> 87

Pro Leu Ser Val Asp Leu Glu Arg Tyr Tyr Gln Thr Glu Asn Glu Asp
 1 5 10 15
 Glu Ser Pro Phe Ile Cys Ser Gln Pro Arg Glu Asn Gly Met Arg Ser
 20 25 30
 Cys Arg Ser Val Pro Thr Leu Arg Gly Asp Gly Gly Gly Pro Pro
 35 40 45
 Cys Gly Leu Asp Tyr Glu Ala Tyr Asn Ser Ser Ser Asn Thr Thr Cys
 50 55 60
 Val Asn Trp Asn Gln Tyr Tyr Thr Asn Cys Ser Ala Gly Glu His Asn
 65 70 75 80
 Pro Phe Lys Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr Ala Trp Ile
 85 90 95
 Ala Ile Phe Gln
 100

<210> 88

<211> 31

<212> PRT

<213> Homo sapiens

<400> 88

Val Ile Thr Leu Glu Gly Trp Val Asp Ile Met Tyr Phe Val Met Asp
 1 5 10 15
 Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile
 20 25 30

<210> 89

<211> 261

<212> PRT

<213> Homo sapiens

<400> 89

```

Val Gly Ser Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr
 1           5           10           15
Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser Gln Leu Met Arg Glu Gln
 20           25           30
Arg Val Arg Phe Leu Ser Asn Ala Ser Thr Leu Ala Ser Phe Ser Glu
 35           40           45
Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys Tyr Leu Val Tyr Ile Leu
 50           55           60
Arg Lys Ala Ala Arg Arg Leu Ala Gln Val Ser Arg Ala Ala Gly Val
 65           70           75           80
Arg Val Gly Leu Leu Ser Ser Pro Ala Pro Leu Gly Gly Gln Glu Thr
 85           90           95
Gln Pro Ser Ser Ser Cys Ser Arg Ser His Arg Arg Leu Ser Val His
100           105           110
His Leu Val His His His His His His His His Tyr His Leu Gly
115           120           125
Asn Gly Thr Leu Arg Ala Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg
130           135           140
Asp Ala Asn Gly Ser Arg Arg Leu Met Leu Pro Pro Pro Ser Thr Pro
145           150           155           160
Ala Leu Ser Gly Ala Pro Pro Gly Gly Ala Glu Ser Val His Ser Phe
165           170           175
Tyr His Ala Asp Cys His Leu Glu Pro Val Arg Cys Gln Ala Pro Pro
180           185           190
Pro Arg Ser Pro Ser Glu Ala Ser Gly Arg Thr Val Gly Ser Gly Lys
195           200           205
Val Tyr Pro Thr Val His Thr Ser Pro Pro Pro Glu Thr Leu Lys Glu
210           215           220
Lys Ala Leu Val Glu Val Ala Ala Ser Ser Gly Pro Pro Thr Leu Thr
225           230           235           240
Ser Leu Asn Ile Pro Pro Gly Pro Tyr Ser Ser Met His Lys Leu Leu
245           250           255
Glu Thr Gln Ser Thr
260

```

<210> 90

<211> 126

<212> PRT

<213> Homo sapiens

<400> 90

```

Gly Ala Cys Gln Ser Ser Cys Lys Ile Ser Ser Pro Cys Leu Lys Ala
 1           5           10           15
Asp Ser Gly Ala Cys Gly Pro Asp Ser Cys Pro Tyr Cys Ala Arg Ala
 20           25           30
Gly Ala Gly Glu Val Glu Leu Ala Asp Arg Glu Met Pro Asp Ser Asp
 35           40           45
Ser Glu Ala Val Tyr Glu Phe Thr Gln Asp Ala Gln His Ser Asp Leu
 50           55           60
Arg Asp Pro His Ser Arg Arg Gln Arg Ser Leu Gly Pro Asp Ala Glu
 65           70           75           80

```

Pro Ser Ser Val Leu Ala Phe Trp Arg Leu Ile Cys Asp Thr Phe Arg
 85 90 95
 Lys Ile Val Asp Ser Lys Tyr Phe Gly Arg Gly Ile Met Ile Ala Ile
 100 105 110
 Leu Val Asn Thr Leu Ser Met Gly Ile Glu Tyr His Glu Gln
 115 120 125

<210> 91
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 91
 Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile Val Phe Thr
 1 5 10 15
 Ser Leu Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Val Tyr Gly Pro
 20 25 30
 Phe Gly Tyr Ile Lys Asn Pro Tyr Asn Ile Phe Asp Gly Val Ile Val
 35 40 45
 Val Ile Ser
 50

<210> 92
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 92
 Val Trp Glu Ile Val Gly Gln Gln Gly Gly Gly Leu Ser Val Leu Arg
 1 5 10 15
 Thr Phe Arg Leu Met Arg Val Leu Lys Leu Val Arg Phe Leu Pro Ala
 20 25 30
 Leu Gln Arg Gln Leu Val Val Leu Met Lys Thr Met Asp Asn Val Ala
 35 40 45
 Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe Ser
 50 55 60

<210> 93
 <211> 38
 <212> PRT
 <213> Homo sapiens

<400> 93
 Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ala Ser Glu Arg Asp
 1 5 10 15
 Gly Asp Thr Leu Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp Ala
 20 25 30
 Ile Val Thr Val Phe Gln
 35

<210> 94
 <211> 52
 <212> PRT
 <213> Homo sapiens

<400> 94

Ile Leu Thr Gln Glu Asp Trp Asn Lys Val Leu Tyr Asn Gly Met Ala
 1 5 10 15
 Ser Thr Ser Ser Trp Ala Ala Leu Tyr Phe Ile Ala Leu Met Thr Phe
 20 25 30
 Gly Asn Tyr Val Leu Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly
 35 40 45
 Phe Gln Ala Glu
 50

<210> 95

<211> 23

<212> PRT

<213> Homo sapiens

<400> 95

Glu Ile Ser Lys Arg Glu Asp Ala Ser Gly Gln Leu Ser Cys Ile Gln
 1 5 10 15
 Leu Pro Val Asp Ser Gln Gly
 20

<210> 96

<211> 28

<212> PRT

<213> Homo sapiens

<400> 96

Gly Asp Ala Asn Lys Ser Glu Ser Glu Pro Asp Phe Phe Ser Pro Ser
 1 5 10 15
 Leu Asp Gly Asp Gly Asp Arg Lys Lys Cys Leu Ala
 20 25

<210> 97

<211> 65

<212> PRT

<213> Homo sapiens

<400> 97

Leu Val Ser Leu Gly Glu His Pro Glu Leu Arg Lys Ser Leu Leu Pro
 1 5 10 15
 Pro Leu Ile Ile His Thr Ala Ala Thr Pro Met Ser Leu Pro Lys Ser
 20 25 30
 Thr Ser Thr Gly Leu Gly Glu Ala Leu Gly Pro Ala Ser Arg Arg Thr
 35 40 45
 Ser Ser Ser Gly Ser Ala Glu Pro Gly Ala Ala His Glu Met Lys Ser
 50 55 60
 Pro
 65

<210> 98

<211> 144

<212> PRT

<213> Homo sapiens

<400> 98

Pro Ser Ala Arg Ser Ser Pro His Ser Pro Trp Ser Ala Ala Ser Ser
 1 5 10 15
 Trp Thr Ser Arg Arg Ser Ser Arg Asn Ser Leu Gly Arg Ala Pro Ser
 20 25 30
 Leu Lys Arg Arg Ser Pro Ser Gly Glu Arg Arg Ser Leu Leu Ser Gly
 35 40 45
 Glu Gly Gln Glu Ser Gln Asp Glu Glu Glu Ser Ser Glu Glu Glu Arg
 50 55 60
 Ala Ser Pro Ala Gly Ser Asp His Arg His Arg Gly Ser Leu Glu Arg
 65 70 75 80
 Glu Ala Lys Ser Ser Phe Asp Leu Pro Asp Thr Leu Gln Val Pro Gly
 85 90 95
 Leu His Arg Thr Ala Ser Gly Arg Gly Ser Ala Ser Glu His Gln Asp
 100 105 110
 Cys Asn Gly Lys Ser Ala Ser Gly Arg Leu Ala Arg Ala Leu Arg Pro
 115 120 125
 Asp Asp Pro Pro Leu Asp Gly Asp Asp Ala Asp Asp Glu Gly Asn Leu
 130 135 140

<210> 99
 <211> 34
 <212> PRT
 <213> Homo sapiens

<400> 99
 Ser Lys Gly Glu Arg Val Arg Ala Trp Ile Arg Ala Arg Leu Pro Ala
 1 5 10 15
 Cys Cys Leu Glu Arg Asp Ser Trp Ser Ala Tyr Ile Phe Pro Pro Gln
 20 25 30
 Ser Arg

<210> 100
 <211> 41
 <212> PRT
 <213> Homo sapiens

<400> 100
 Phe Arg Leu Leu Cys His Arg Ile Ile Thr His Lys Met Phe Asp His
 1 5 10 15
 Val Val Leu Val Ile Ile Phe Leu Asn Cys Ile Thr Ile Ala Met Glu
 20 25 30
 Arg Pro Lys Ile Asp Pro His Ser Ala
 35 40

<210> 101
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 101
 Glu Arg Ile Phe Leu Thr Leu Ser Asn Tyr Ile Phe Thr Ala Val Phe
 1 5 10 15
 Leu Ala Glu Met Thr Val Lys
 20

<210> 102
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 102
 Val Val Ala Leu Gly Trp Cys Phe Gly Glu Gln Ala Tyr Leu Arg Ser
 1 5 10 15
 Ser Trp Asn Val Leu Asp Gly Leu Leu Val Leu Ile Ser Val Ile Asp
 20 25 30
 Ile Leu Val Ser Met Val Ser Asp Ser Gly Thr Lys Ile Leu Gly Met
 35 40 45
 Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg
 50 55 60

<210> 103
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 103
 Val Ile Ser Arg Ala Gln Gly Leu Lys Leu Val Val Glu Thr Leu Met
 1 5 10 15
 Ser Ser Leu Lys Pro Ile Gly Asn Ile Val Val Ile Cys Cys Ala Phe
 20 25 30
 Phe Ile Ile Phe Gly Ile Leu Gly Val Gln
 35 40

<210> 104
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 104
 Leu Phe Lys Gly Lys Phe Phe Val Cys Gln Gly Glu Asp Thr Arg Asn
 1 5 10 15
 Ile Thr Asn Lys Ser Asp Cys Ala Glu Ala Ser Tyr Arg Trp Val Arg
 20 25 30
 His Lys Tyr Asn Phe Asp Asn Leu Gly Gln
 35 40

<210> 105
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 105
 Ala Leu Met Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asp
 1 5 10 15
 Ile Met Tyr Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln
 20 25 30

<210> 106
 <211> 64
 <212> PRT

<213> Homo sapiens

<400> 106

```

Pro Ile Met Asn His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe
 1             5             10             15
Leu Leu Ile Val Ala Phe Phe Val Leu Asn Met Phe Val Gly Val Val
                20             25             30
Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu Glu Glu Ala
                35             40             45
Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg
 50             55             60

```

<210> 107

<211> 7

<212> PRT

<213> Homo sapiens

<400> 107

```

Ser Lys Glu Lys Gln Met Ala
 1             5

```

<210> 108

<211> 18

<212> PRT

<213> Homo sapiens

<400> 108

```

Asn Leu Met Leu Asp Asp Val Ile Ala Ser Gly Ser Ser Ala Ser Ala
 1             5             10             15
Ala Ser

```

<210> 109

<211> 51

<212> PRT

<213> Homo sapiens

<400> 109

```

Glu Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe Arg Leu
 1             5             10             15
Leu Val His His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr
                20             25             30
Gly Val Ile Gly Leu Asn Val Val Thr Met Ala Met Glu His Tyr Gln
                35             40             45
Gln Pro Gln
 50

```

<210> 110

<211> 37

<212> PRT

<213> Homo sapiens

<400> 110

```

Ile Leu Asp Glu Ala Leu Lys Ile Cys Asn Tyr Ile Phe Thr Val Ile
 1             5             10             15

```

Phe Val Leu Glu Ser Val Phe Lys Leu Val Ala Phe Gly Phe Arg Arg
 20 25 30

Phe Phe Gln Asp Arg
 35

<210> 111
 <211> 44
 <212> PRT
 <213> Homo sapiens

<400> 111

Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Ile Met Gly Ile
 1 5 10 15

Thr Leu Glu Glu Ile Glu Val Asn Ala Ser Leu Pro Ile Asn Pro Thr
 20 25 30

Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg
 35 40

<210> 112
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 112

Val Leu Lys Leu Leu Lys Met Ala Val Gly Met Arg Ala Leu Leu Asp
 1 5 10 15

Thr Val Met Gln Ala Leu Pro Gln
 20

<210> 113
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 113

Val Gly Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile Phe Ala
 1 5 10 15

Ala Leu Gly Val Glu Leu Phe Gly Asp Leu
 20 25

<210> 114
 <211> 41
 <212> PRT
 <213> Homo sapiens

<400> 114

Glu/Cys Asp Glu Thr His Pro Cys Glu Gly Leu Gly Arg His Ala Thr
 1 5 10 15

Phe Arg Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser Thr
 20 25 30

Gly Asp Asn Trp Asn Gly Ile Met Lys
 35 40

<210> 115
 <211> 118

<212> PRT

<213> Homo sapiens

<400> 115

```

Asp Thr Leu Arg Asp Cys Asp Gln Glu Ser Thr Cys Tyr Asn Thr Val
 1           5           10           15
Ile Ser Pro Ile Tyr Phe Val Ser Phe Val Leu Thr Ala Gln Phe Val
          20           25           30
Leu Val Asn Val Val Ile Ala Val Leu Met Lys His Leu Glu Glu Ser
          35           40           45
Asn Lys Glu Ala Lys Glu Glu Ala Glu Leu Glu Ala Glu Leu Glu Leu
          50           55           60
Glu Met Lys Thr Leu Ser Pro Gln Pro His Ser Pro Leu Gly Ser Pro
65           70           75           80
Phe Leu Trp Pro Gly Val Glu Gly Pro Asp Ser Pro Asp Ser Pro Lys
          85           90           95
Pro Gly Ala Leu His Pro Ala Ala His Ala Arg Ser Ala Ser His Phe
          100          105          110
Ser Leu Glu His Pro Thr
          115

```

<210> 116

<211> 48

<212> PRT

<213> Homo sapiens

<400> 116

```

Asp Arg Gln Leu Phe Asp Thr Ile Ser Leu Leu Ile Gln Gly Ser Leu
 1           5           10           15
Glu Trp Glu Leu Lys Leu Met Asp Glu Leu Ala Gly Pro Gly Gly Gln
          20           25           30
Pro Ser Ala Phe Pro Ser Ala Pro Ser Leu Gly Gly Ser Asp Pro Gln
          35           40           45

```

<210> 117

<211> 45

<212> PRT

<213> Homo sapiens

<400> 117

```

Ile Pro Leu Ala Glu Met Glu Ala Leu Ser Leu Thr Ser Glu Ile Val
 1           5           10           15
Ser Glu Pro Ser Cys Ser Leu Ala Leu Thr Asp Asp Ser Leu Pro Asp
          20           25           30
Asp Met His Thr Leu Leu Leu Ser Ala Leu Glu Ser Asn
          35           40           45

```

<210> 118

<211> 56

<212> PRT

<213> Homo sapiens

<400> 118

```

Met Gln Pro His Pro Thr Glu Leu Pro Gly Pro Asp Leu Leu Thr Val
 1           5           10           15

```

Arg Lys Ser Gly Val Ser Arg Thr His Ser Leu Pro Asn Asp Ser Tyr
 20 25 30
 Met Cys Arg His Gly Ser Thr Ala Glu Gly Pro Leu Gly His Arg Gly
 35 40 45
 Trp Gly Leu Pro Lys Ala Gln Ser
 50 55

<210> 119
 <211> 57
 <212> PRT
 <213> Homo sapiens

<400> 119
 Gly Ser Val Leu Ser Val His Ser Gln Pro Ala Asp Thr Ser Tyr Ile
 1 5 10 15
 Leu Gln Leu Pro Lys Asp Ala Pro His Leu Leu Gln Pro His Ser Ala
 20 25 30
 Pro Thr Trp Gly Thr Ile Pro Lys Leu Pro Pro Pro Gly Arg Ser Pro
 35 40 45
 Leu Ala Gln Arg Pro Leu Arg Arg Gln
 50 55

<210> 120
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 120
 Ala Ala Ile Arg Thr Asp Ser Leu Asp Val Gln Gly Leu Gly Ser Arg
 1 5 10 15
 Glu Asp Leu Leu Ala Glu
 20

<210> 121
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 121
 Val Ser Gly Pro Ser Pro Pro Leu Ala Arg Ala Tyr Ser Phe Trp Gly
 1 5 10 15
 Gln Ser Ser Thr Gln Ala Gln Gln His Ser Arg Ser His Ser Lys Ile
 20 25 30
 Ser Lys His Met Thr Pro Pro Ala Pro Cys Pro Gly Pro Glu Pro Asn
 35 40 45
 Trp Gly Lys Gly Pro Pro Glu Thr Arg Ser Ser Leu Glu Leu Asp Thr
 50 55 60
 Glu Leu Ser Trp Ile Ser Gly Asp Leu Leu Pro Pro Gly Gly Gln
 65 70 75

<210> 122
 <211> 143
 <212> PRT
 <213> Homo sapiens

<400> 122
 Glu Glu Pro Pro Ser Pro Arg Asp Leu Lys Lys Cys Tyr Ser Val Glu
 1 5 10 15
 Ala Gln Ser Cys Gln Arg Arg Pro Thr Ser Trp Leu Asp Glu Gln Arg
 20 25 30
 Arg His Ser Ile Ala Val Ser Cys Leu Asp Ser Gly Ser Gln Pro His
 35 40 45
 Leu Gly Thr Asp Pro Ser Asn Leu Gly Gly Gln Pro Leu Gly Gly Pro
 50 55 60
 Gly Ser Arg Pro Lys Lys Lys Leu Ser Pro Pro Ser Ile Thr Ile Asp
 65 70 75 80
 Pro Pro Glu Ser Gln Gly Pro Arg Thr Pro Pro Ser Pro Gly Ile Cys
 85 90 95
 Leu Arg Arg Arg Ala Pro Ser Ser Asp Ser Lys Asp Pro Leu Ala Ser
 100 105 110
 Gly Pro Pro Asp Ser Met Ala Ala Ser Pro Ser Pro Lys Lys Asp Val
 115 120 125
 Leu Ser Leu Ser Gly Leu Ser Ser Asp Pro Ala Asp Leu Asp Pro
 130 135 140

<210> 123
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 123
 Met Ala Glu Ser Ala Ser Pro Pro Ser Ser Ser Ala Ala Ala Pro Ala
 1 5 10 15
 Ala Glu Pro Gly Val Thr Thr Glu Gln Pro Gly Pro Arg Ser Pro Pro
 20 25 30
 Ser Ser Pro Pro Gly Leu Glu Glu Pro Leu Asp Gly Ala Asp Pro His
 35 40 45
 Val Pro His Pro Asp Leu Ala Pro Ile Ala Phe Phe Cys Leu Arg Gln
 50 55 60
 Thr Thr Ser Pro Arg Asn Trp Cys Ile Lys Met Val Cys Asn Pro
 65 70 75

<210> 124
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 124
 Trp Phe Glu Cys Val Ser Met Leu Val Ile Leu Leu Asn Cys Val Thr
 1 5 10 15
 Leu Gly Met Tyr Gln Pro Cys Asp Asp Met Asp Cys Leu Ser Asp Arg
 20 25 30
 Cys Lys Ile Leu Gln
 35

<210> 125
 <211> 45
 <212> PRT
 <213> Homo sapiens

<400> 125

Val Phe Asp Asp Phe Ile Phe Ile Phe Phe Ala Met Glu Met Val Leu
 1 5 10 15
 Lys Met Val Ala Leu Gly Ile Phe Gly Lys Lys Cys Tyr Leu Gly Asp
 20 25 30
 Thr Trp Asn Arg Leu Asp Phe Phe Ile Val Met Ala Gly
 35 40 45

<210> 126

<211> 32

<212> PRT

<213> Homo sapiens

<400> 126

Met Val Glu Tyr Ser Leu Asp Leu Gln Asn Ile Asn Leu Ser Ala Ile
 1 5 10 15
 Arg Thr Val Arg Val Leu Arg Pro Leu Lys Ala Ile Asn Arg Val Pro
 20 25 30

<210> 127

<211> 54

<212> PRT

<213> Homo sapiens

<400> 127

Ser Met Arg Ile Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu
 1 5 10 15
 Gly Asn Val Leu Leu Cys Phe Phe Val Phe Phe Ile Phe Gly Ile
 20 25 30
 Ile Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu
 35 40 45
 Glu Glu Asn Phe Thr Ile
 50

<210> 128

<211> 105

<212> PRT

<213> Homo sapiens

<400> 128

Gln Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gln Pro Glu Glu Asp Asp
 1 5 10 15
 Glu Met Pro Phe Ile Cys Ser Leu Ser Gly Asp Asn Gly Ile Met Gly
 20 25 30
 Cys His Glu Ile Pro Pro Leu Lys Glu Gln Gly Arg Glu Cys Cys Leu
 35 40 45
 Ser Lys Asp Asp Val Tyr Asp Phe Gly Ala Gly Arg Gln Asp Leu Asn
 50 55 60
 Ala Ser Gly Leu Cys Val Asn Trp Asn Arg Tyr Tyr Asn Val Cys Arg
 65 70 75 80
 Thr Gly Ser Ala Asn Pro His Lys Gly Ala Ile Asn Phe Asp Asn Ile
 85 90 95
 Gly Tyr Ala Trp Ile Val Ile Phe Gln
 100 105

<210> 129
 <211> 31
 <212> PRT
 <213> Homo sapiens

<400> 129
 Val Ile Thr Leu Glu Gly Trp Val Glu Ile Met Tyr Tyr Val Met Asp
 1 5 10 15
 Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile
 20 25 30

<210> 130
 <211> 104
 <212> PRT
 <213> Homo sapiens

<400> 130
 Val Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr
 1 5 10 15
 Gln Phe Ser Glu Thr Lys Gln Arg Glu His Arg Leu Met Leu Glu Gln
 20 25 30
 Arg Gln Arg Tyr Leu Ser Ser Ser Thr Val Ala Ser Tyr Ala Glu Pro
 35 40 45
 Gly Asp Cys Tyr Glu Glu Ile Phe Gln Tyr Val Cys His Ile Leu Arg
 50 55 60
 Lys Ala Lys Arg Arg Ala Leu Gly Leu Tyr Gln Ala Leu Gln Ser Arg
 65 70 75 80
 Arg Gln Ala Leu Gly Pro Glu Ala Pro Ala Pro Ala Lys Pro Gly Pro
 85 90 95
 His Ala Lys Glu Pro Arg His Tyr
 100

<210> 131
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 131
 His Gly Lys Thr Lys Gly Gln Gly Asp Glu Gly Arg His Leu Gly Ser
 1 5 10 15
 Arg His Cys Gln Thr Leu His Gly Pro Ala Ser Pro Gly Asn Asp His
 20 25 30
 Ser Gly Arg
 35

<210> 132
 <211> 142
 <212> PRT
 <213> Homo sapiens

<400> 132
 Glu Leu Cys Pro Gln His Ser Pro Leu Asp Ala Thr Pro His Thr Leu
 1 5 10 15
 Val Gln Pro Ile Pro Ala Thr Leu Ala Ser Asp Pro Ala Ser Cys Pro
 20 25 30

Cys Cys Gln His Glu Asp Gly Arg Arg Pro Ser Gly Leu Gly Ser Thr
 35 40 45
 Asp Ser Gly Gln Glu Gly Ser Gly Ser Gly Ser Ser Ala Gly Gly Glu
 50 55 60
 Asp Glu Ala Asp Gly Asp Gly Ala Arg Ser Ser Glu Asp Gly Ala Ser
 65 70 75 80
 Ser Glu Leu Gly Lys Glu Glu Glu Glu Glu Glu Gln Ala Asp Gly Ala
 85 90 95
 Val Trp Leu Cys Gly Asp Val Trp Arg Glu Thr Arg Ala Lys Leu Arg
 100 105 110
 Gly Ile Val Asp Ser Lys Tyr Phe Asn Arg Gly Ile Met Met Ala Ile
 115 120 125
 Leu Val Asn Thr Val Ser Met Gly Ile Glu His His Glu Gln
 130 135 140

<210> 133
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 133
 Pro Glu Glu Leu Thr Asn Ile Leu Glu Ile Cys Asn Val Val Phe Thr
 1 5 10 15
 Ser Met Phe Ala Leu Glu Met Ile Leu Lys Leu Ala Ala Phe Gly Leu
 20 25 30
 Phe Asp Tyr Leu Arg Asn Pro Tyr Asn Ile Phe Asp Ser Ile Ile Val
 35 40 45
 Ile Ile Ser
 50

<210> 134
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 134
 Ile Trp Glu Ile Val Gly Gln Ala Asp Gly Gly Leu Ser Val Leu Arg
 1 5 10 15
 Thr Phe Arg Leu Leu Arg Val Leu Lys Leu Val Arg Phe Met Pro Ala
 20 25 30
 Leu Arg Arg Gln Leu Val Val Leu Met Lys Thr Met Asp Asn Val Ala
 35 40 45
 Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe Ser
 50 55 60

<210> 135
 <211> 39
 <212> PRT
 <213> Homo sapiens

<400> 135
 Ile Leu Gly Met His Ile Phe Gly Cys Lys Phe Ser Leu Arg Thr Asp
 1 5 10 15
 Thr Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp
 20 25 30

Ala Ile Val Thr Val Phe Gln
35

<210> 136
<211> 52
<212> PRT
<213> Homo sapiens

<400> 136
Ile Leu Thr Gln Glu Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala
1 5 10 15
Ser Thr Ser Pro Trp Ala Ser Leu Tyr Phe Val Ala Leu Met Thr Phe
20 25 30
Gly Asn Tyr Val Leu Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly
35 40 45
Phe Gln Ala Glu
50

<210> 137
<211> 31
<212> PRT
<213> Homo sapiens

<400> 137
Gly Asp Ala Asn Arg Ser Tyr Ser Asp Glu Asp Gln Ser Ser Ser Asn
1 5 10 15
Ile Glu Glu Phe Asp Lys Leu Gln Glu Gly Leu Asp Ser Ser Gly
20 25 30

<210> 138
<211> 68
<212> PRT
<213> Homo sapiens

<400> 138
Asp Pro Lys Leu Cys Pro Ile Pro Met Thr Pro Asn Gly His Leu Asp
1 5 10 15
Pro Ser Leu Pro Leu Gly Gly His Leu Gly Pro Ala Gly Ala Ala Gly
20 25 30
Pro Ala Pro Arg Leu Ser Leu Gln Pro Asp Pro Met Leu Val Ala Leu
35 40 45
Gly Ser Arg Lys Ser Ser Val Met Ser Leu Gly Arg Met Ser Tyr Asp
50 55 60
Gln Arg Ser Leu
65

<210> 139
<211> 157
<212> PRT
<213> Homo sapiens

<400> 139
Ser Ser Ser Arg Ser Ser Tyr Tyr Gly Pro Trp Gly Arg Ser Ala Ala
1 5 10 15
Trp Ala Ser Arg Arg Ser Ser Trp Asn Ser Leu Lys His Lys Pro Pro

```

                20                25                30
Ser Ala Glu His Glu Ser Leu Leu Ser Ala Glu Arg Gly Gly Gly Ala
   35                40                45
Arg Val Cys Glu Val Ala Ala Asp Glu Gly Pro Pro Arg Ala Ala Pro
   50                55                60
Leu His Thr Pro His Ala His His Ile His His Gly Pro His Leu Ala
   65                70                75                80
His Arg His Arg His His Arg Arg Thr Leu Ser Leu Asp Asn Arg Asp
   85                90                95
Ser Val Asp Leu Ala Glu Leu Val Pro Ala Val Gly Ala His Pro Arg
   100                105                110
Ala Ala Trp Arg Ala Ala Gly Pro Ala Pro Gly His Glu Asp Cys Asn
   115                120                125
Gly Arg Met Pro Ser Ile Ala Lys Asp Val Phe Thr Lys Met Gly Asp
   130                135                140
Arg Gly Asp Arg Gly Glu Asp Glu Glu Glu Ile Asp Tyr
145                150                155

```

<210> 140
 <211> 34
 <212> PRT
 <213> Homo sapiens

```

<400> 140
Thr Leu Cys Phe Arg Val Arg Lys Met Ile Asp Val Tyr Lys Pro Asp
  1                5                10                15
Trp Cys Glu Val Arg Glu Asp Trp Ser Val Tyr Leu Phe Ser Pro Glu
   20                25                30
Asn Arg

```

<210> 141
 <211> 41
 <212> PRT
 <213> Homo sapiens

```

<400> 141
Phe Arg Val Leu Cys Gln Thr Ile Ile Ala His Lys Leu Phe Asp Tyr
  1                5                10                15
Val Val Leu Ala Phe Ile Phe Leu Asn Cys Ile Thr Ile Ala Leu Glu
   20                25                30
Arg Pro Gln Ile Glu Ala Gly Ser Thr
   35                40

```

<210> 142
 <211> 23
 <212> PRT
 <213> Homo sapiens

```

<400> 142
Glu Arg Ile Phe Leu Thr Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe
  1                5                10                15
Val Gly Glu Met Thr Leu Lys
   20

```

<210> 143
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 143
 Val Val Ser Leu Gly Leu Tyr Phe Gly Glu Gln Ala Tyr Leu Arg Ser
 1 5 10 15
 Ser Trp Asn Val Leu Asp Gly Phe Leu Val Phe Val Ser Ile Ile Asp
 20 25 30
 Ile Val Val Ser Leu Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val
 35 40 45
 Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg
 50 55 60

<210> 144
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 144
 Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu Thr Leu Ile
 1 5 10 15
 Ser Ser Leu Lys Pro Ile Gly Asn Ile Val Leu Ile Cys Cys Ala Phe
 20 25 30
 Phe Ile Ile Phe Gly Ile Leu Gly Val Gln
 35 40

<210> 145
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 145
 Leu Phe Lys Gly Lys Phe Tyr His Cys Leu Gly Val Asp Thr Arg Asn
 1 5 10 15
 Ile Thr Asn Arg Ser Asp Cys Met Ala Ala Asn Tyr Arg Trp Val His
 20 25 30
 His Lys Tyr Asn Phe Asp Asn Leu Gly Gln
 35 40

<210> 146
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 146
 Ala Leu Met Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asn
 1 5 10 15
 Ile Met Tyr Asn Gly Leu Asp Ala Val Ala Val Asp Gln Gln
 20 25 30

<210> 147
 <211> 64
 <212> PRT

<213> Homo sapiens

<400> 147

```

Pro Val Thr Asn His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe
 1              5              10              15
Leu Leu Ile Val Ser Phe Phe Val Leu Asn Met Phe Val Gly Val Val
                20              25              30
Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu Ala Glu Glu Ala
 35              40              45
Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg
 50              55              60

```

<210> 148

<211> 51

<212> PRT

<213> Homo sapiens

<400> 148

```

Lys Ala Gln Arg Leu Pro Tyr Tyr Ala Thr Tyr Cys His Thr Arg Leu
 1              5              10              15
Leu Ile His Ser Met Cys Thr Ser His Tyr Leu Asp Ile Phe Ile Thr
                20              25              30
Phe Ile Ile Cys Leu Asn Val Val Thr Met Ser Leu Glu His Tyr Asn
 35              40              45
Gln Pro Thr
 50

```

<210> 149

<211> 37

<212> PRT

<213> Homo sapiens

<400> 149

```

Ser Leu Glu Thr Ala Leu Lys Tyr Cys Asn Tyr Met Phe Thr Thr Val
 1              5              10              15
Phe Val Leu Glu Ala Val Leu Lys Leu Val Ala Phe Gly Leu Arg Arg
                20              25              30
Phe Phe Lys Asp Arg
 35

```

<210> 150

<211> 44

<212> PRT

<213> Homo sapiens

<400> 150

```

Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Val Met Gly Ile
 1              5              10              15
Thr Leu Glu Glu Ile Glu Ile Asn Ala Ala Leu Pro Ile Asn Pro Thr
                20              25              30
Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg
 35              40

```

<210> 151

<211> 24

<212> PRT

<213> Homo sapiens

<400> 151

Val Leu Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp
 1 5 10 15
 Thr Val Val Gln Ala Leu Pro Gln
 20

<210> 152

<211> 26

<212> PRT

<213> Homo sapiens

<400> 152

Val Gly Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile Tyr Ala
 1 5 10 15
 Ala Leu Gly Val Glu Leu Phe Gly Lys Leu
 20 25

<210> 153

<211> 41

<212> PRT

<213> Homo sapiens

<400> 153

Val Cys Asn Asp Glu Asn Pro Cys Glu Gly Met Ser Arg His Ala Thr
 1 5 10 15
 Phe Glu Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Gln Val Ser Thr
 20 25 30
 Gly Asp Asn Trp Asn Gly Ile Met Lys
 35 40

<210> 154

<211> 113

<212> PRT

<213> Homo sapiens

<400> 154

Asp Thr Leu Arg Asp Cys Thr His Asp Glu Arg Ser Cys Leu Ser Ser
 1 5 10 15
 Leu Gln Phe Val Ser Pro Leu Tyr Phe Val Ser Phe Val Leu Thr Ala
 20 25 30
 Gln Phe Val Leu Ile Asn Val Val Val Ala Val Leu Met Lys His Leu
 35 40 45
 Asp Asp Ser Asn Lys Glu Ala Gln Glu Asp Ala Glu Met Asp Ala Glu
 50 55 60
 Leu Glu Leu Glu Met Ala His Gly Leu Gly Pro Gly Pro Arg Leu Pro
 65 70 75 80
 Thr Gly Ser Pro Gly Ala Pro Gly Arg Gly Pro Gly Gly Ala Gly Gly
 85 90 95
 Gly Gly Asp Thr Glu Gly Gly Leu Cys Arg Arg Cys Tyr Ser Pro Ala
 100 105 110
 Gln

<210> 155
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 155
 Glu Asn Leu Trp Leu Asp Ser Val Ser Leu Ile Ile Lys
 1 5 10

<210> 156
 <211> 36
 <212> PRT
 <213> Homo sapiens

<400> 156
 Asp Ser Leu Glu Gly Glu Leu Thr Ile Ile Asp Asn Leu Ser Gly Ser
 1 5 10 15
 Ile Phe His His Tyr Ser Ser Pro Ala Gly Cys Lys Lys Cys His His
 20 25 30
 Asp Lys Gln Glu
 35

<210> 157
 <211> 41
 <212> PRT
 <213> Homo sapiens

<400> 157
 Val Gln Leu Ala Glu Thr Glu Ala Phe Ser Leu Asn Ser Asp Arg Ser
 1 5 10 15
 Ser Ser Ile Leu Leu Gly Asp Asp Leu Ser Leu Glu Asp Pro Thr Ala
 20 25 30
 Cys Pro Pro Gly Arg Lys Asp Ser Lys
 35 40

<210> 158
 <211> 55
 <212> PRT
 <213> Homo sapiens

<400> 158
 Gly Glu Leu Asp Pro Pro Glu Pro Met Arg Val Gly Asp Leu Gly Glu
 1 5 10 15
 Cys Phe Phe Pro Leu Ser Ser Thr Ala Val Ser Pro Asp Pro Glu Asn
 20 25 30
 Phe Leu Cys Glu Met Glu Glu Ile Pro Phe Asn Pro Val Arg Ser Trp
 35 40 45
 Leu Lys His Asp Ser Ser Gln
 50 55

<210> 159
 <211> 66
 <212> PRT
 <213> Homo sapiens

<400> 159
 Ala Pro Pro Ser Pro Phe Ser Pro Asp Ala Ser Ser Pro Leu Leu Pro
 1 5 10 15
 Met Pro Ala Glu Phe Phe His Pro Ala Val Ser Ala Ser Gln Lys Gly
 20 25 30
 Pro Glu Lys Gly Thr Gly Thr Gly Thr Leu Pro Lys Ile Ala Leu Gln
 35 40 45
 Gly Ser Trp Ala Ser Leu Arg Ser Pro Arg Val Asn Cys Thr Leu Leu
 50 55 60
 Arg Gln
 65

<210> 160
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 160
 Val Pro Thr Pro Pro Arg Pro
 1 5

<210> 161
 <211> 214
 <212> PRT
 <213> Homo sapiens

<400> 161
 Ala Thr Gly Ser Asp Thr Ser Leu Asp Ala Ser Pro Ser Ser Ser Ala
 1 5 10 15
 Gly Ser Leu Gln Thr Thr Leu Glu Asp Ser Leu Thr Leu Ser Asp Ser
 20 25 30
 Pro Arg Arg Ala Leu Gly Pro Pro Ala Pro Ala Pro Gly Pro Arg Ala
 35 40 45
 Gly Leu Ser Pro Ala Ala Arg Arg Arg Leu Ser Leu Arg Gly Arg Gly
 50 55 60
 Leu Phe Ser Leu Arg Gly Leu Arg Ala His Gln Arg Ser His Ser Ser
 65 70 75 80
 Gly Gly Ser Thr Ser Pro Gly Cys Thr His His Asp Ser Met Asp Pro
 85 90 95
 Ser Asp Glu Glu Gly Arg Gly Gly Ala Gly Gly Gly Ala Gly Ser
 100 105 110
 Glu His Ser Glu Thr Leu Ser Ser Leu Ser Leu Thr Ser Leu Phe Cys
 115 120 125
 Pro Pro Pro Pro Pro Ala Pro Gly Leu Thr Pro Ala Arg Lys Phe
 130 135 140
 Ser Ser Thr Ser Ser Leu Ala Ala Pro Gly Arg Pro His Ala Ala Ala
 145 150 155 160
 Leu Ala His Gly Leu Ala Arg Ser Pro Ser Trp Ala Ala Asp Arg Ser
 165 170 175
 Lys Asp Pro Pro Gly Arg Ala Pro Leu Pro Met Gly Leu Gly Pro Leu
 180 185 190
 Ala Pro Pro Pro Gln Pro Leu Pro Gly Glu Leu Glu Pro Gly Asp Ala
 195 200 205
 Ala Ser Lys Arg Lys Arg
 210

<210> 162
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 162
 Asp Leu Met Leu Asp Asp Val Ile Ala Ser Gly Ser Ser Ala Ser Ala
 1 5 10 15
 Ala Ser

<210> 163
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 163
 Lys Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe Arg Leu
 1 5 10 15
 Leu Val His His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr
 20 25 30
 Gly Val Ile Gly Leu Asn Val Val Thr Met Ala Met Glu His Tyr Gln
 35 40 45
 Gln Pro Gln
 50

<210> 164
 <211> 142
 <212> PRT
 <213> Homo sapiens

<400> 164
 Gln Leu Cys Pro Gln His Ser Pro Leu Asp Ala Thr Pro His Thr Leu
 1 5 10 15
 Val Gln Pro Ile Pro Ala Thr Leu Ala Ser Asp Pro Ala Ser Cys Pro
 20 25 30
 Cys Cys Gln His Glu Asp Gly Arg Arg Pro Ser Gly Leu Gly Ser Thr
 35 40 45
 Asp Ser Gly Gln Glu Gly Ser Gly Ser Ser Ala Gly Gly Glu
 50 55 60
 Asp Glu Ala Asp Gly Asp Gly Ala Arg Ser Ser Glu Asp Gly Ala Ser
 65 70 75 80
 Ser Glu Leu Gly Lys Glu Glu Glu Glu Glu Gln Ala Asp Gly Ala
 85 90 95
 Val Trp Leu Cys Gly Asp Val Trp Arg Glu Thr Arg Ala Lys Leu Arg
 100 105 110
 Gly Ile Val Asp Ser Lys Tyr Phe Asn Arg Gly Ile Met Met Ala Ile
 115 120 125
 Leu Val Asn Thr Val Ser Met Gly Ile Glu His His Glu Gln
 130 135 140

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 November 2000 (23.11.2000)

PCT

(10) International Publication Number
WO 00/70044 A3

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/705, G01N 33/68

(72) Inventors; and

(21) International Application Number: PCT/US00/12383

(75) Inventors/Applicants (for US only): MITTMAN, Scott
[US/US]; The Johns Hopkins University, 111 Market
Place, Baltimore, MD 21201 (US). AGNEW, William,
S. [US/US]; The Johns Hopkins University, 111 Market
Place, Baltimore, MD 21201 (US).

(22) International Filing Date: 8 May 2000 (08.05.2000)

(25) Filing Language: English

(74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff,
Ltd., Eleventh Floor, 1001 G Street, N.W., Washington, DC
20001-4597 (US).

(26) Publication Language: English

(30) Priority Data:

60/134,063 13 May 1999 (13.05.1999) US


60/137,547 4 June 1999 (04.06.1999) US

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (for all designated States except US): THE
JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market
Place, Baltimore, MD 21201 (US).

[Continued on next page]

(54) Title: HUMAN BRAIN T CALCIUM CHANNEL ALPHA-SUBUNIT SPLICE VARIANTS



(57) Abstract: The structures of *CACNA1G* and *CACNA1I*, the genes encoding the human brain T Ca^{2+} channel α_{1G} and α_{1I} subunits, respectively, were determined by comparison of polymerase chain reaction-amplified brain cDNA and genomic sequences. *CACNA1G* consists of at least 38 exons spanning at least 66,490 basepairs of chromosome 17q22. Alternative splicing of the RNA occurs at six sites: cassette exons 14, 26, 34 and 35, an internal donor in exon 25 and protein-coding intron 38B. Additionally, the RNA can be polyadenylated at either of two sites. Alternative splicing of *CACNA1G* RNA may lead to expression of as many as 64 distinct protein products, ranging from 2,171 to 2,377 amino-acids residues, with as many as 45 potential phosphorylation sites. *CACNA1I* consists of at least 37 exons spanning at least 116,390 basepairs of chromosome 22q12.3-13.2. Alternative splicing of the gene occurs at three sites: cassette exon 9, an alternative acceptor in exon 33 and mutually-exclusive 3' exons 36B and 37. Alternative splicing of *CACNA1I* RNA may lead to expression of as many as 8 distinct protein products, ranging from 1,968 to 2,223 amino-acids residues, with as many as 28 potential phosphorylation sites. Molecular diversity generated by alternative splicing and post-translation modification of these and other members of the T α_1 subunit gene family may account for the observed heterogeneity of T currents in central neurons.



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
17 May 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— With international search report.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/12383

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EP0-Internal, EMBL, WPI Data, MEDLINE, EMBASE, SCISEARCH, BIOTECHNOLOGY
ABS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PEREZ-REYES EDWARD ET AL: "Molecular characterization of a neuronal low-voltage-activated T-type calcium channel." NATURE (LONDON), vol. 391, no. 6670, 26 February 1998 (1998-02-26), pages 896-900, XP002147614 ISSN: 0028-0836 abstract; figure 1 page 896, right-hand column, paragraph 3 --- -/--</p>	<p>1-5,11, 12,15, 16,19,20</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 September 2000

Date of mailing of the international search report

22.12.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/12383

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-5, 11, 12, 15,16,19, 20

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/12383

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CRIBBS LEANNE L ET AL: "Cloning and characterization of alpha1H from human heart, a member of the T-type Ca ²⁺ channel gene family." CIRCULATION RESEARCH, vol. 83, no. 1, 13 July 1998 (1998-07-13), pages 103-109, XP000938541 ISSN: 0009-7330 abstract; figure 1 ---	1-5,11, 12,15, 16,19,20
X	DATABASE EMBL [Online] Accession number ab012043, 8 January 1999 (1999-01-08) KISHI F.: "Homo sapiens mRNA for NBR13" XP002147615 abstract ---	4,5
X	-& DATABASE TREMBL [Online] Accession number 094770, 1 May 1999 (1999-05-01) KISHI F.: "Human NBR13" XP002147616 abstract ---	4,5
A	WILLIAMS M E ET AL: "Cloning and characterization of a novel human Ca ²⁺ channel alpha1 subunit associated with a low-voltage activated (LVA) Ca ²⁺ channel." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, page 1823 XP000938545 28th Annual Meeting of the Society for Neuroscience, Part 2; Los Angeles, California, USA; November 7-12, 1998 ISSN: 0190-5295 the whole document ---	1-5,11, 12,15, 16,19,20
A	WILLIAMS MARK E ET AL: "Structure and functional characterization of a novel human low-voltage activated calcium channel." JOURNAL OF NEUROCHEMISTRY, vol. 72, no. 2, February 1999 (1999-02), pages 791-799, XP000938528 ISSN: 0022-3042 the whole document --- -/--	1-5,11, 12,15, 16,19,20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/12383

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LEE JUNG-HA ET AL: "Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family." JOURNAL OF NEUROSCIENCE, vol. 19, no. 6, 15 March 1999 (1999-03-15), pages 1912-1921, XP000946046 ISSN: 0270-6474 the whole document</p>	1-5,11, 12
P,X	<p>MITTMAN S ET AL: "Structure and alternative splicing of the genes encoding the human brain T Ca2+ channel subunits alpha1G and alpha1I." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, page 197 XP000938544 29th Annual Meeting of the Society for Neuroscience, Part 1;Miami Beach, Florida, USA; October 23-28, 1999 ISSN: 0190-5295 the whole document</p>	1-5,11, 12
P,X	<p>MITTMAN SCOTT ET AL: "Structure and alternative splicing of the gene encoding alpha1G, a human brain T calcium channel alpha1 subunit." NEUROSCIENCE LETTERS, vol. 274, no. 3, 29 October 1999 (1999-10-29), pages 143-146, XP000946163 ISSN: 0304-3940 the whole document</p>	1-5,11, 12
P,X	<p>CRIBBS LEANNE L ET AL: "Molecular cloning and functional expression of Cav3.1c, a T-type calcium channel from human brain." FEBS LETTERS, vol. 469, no. 1, 21 January 2000 (2000-01-21), pages 54-58, XP000938714 ISSN: 0014-5793 the whole document</p>	1-5,11, 12
P,X	<p>MONTEIL ARNAUD ET AL: "Molecular and functional properties of the human alpha1G subunit that forms T-type calcium channels." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 9, 3 March 2000 (2000-03-03), pages 6090-6100, XP000938755 ISSN: 0021-9258 abstract; figures 2,3</p>	1-5,11, 12
-/--		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/12383

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 29847 A (UNIV LOYOLA CHICAGO ;CRIBBS LEANNE L (US); PEREZ REYES EDWARD (US)) 17 June 1999 (1999-06-17) figures SEQ.1-11; example 1 -----	1-5,11, 12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/12383

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9929847 A	17-06-1999	EP 1036170 A	20-09-2000
